Congratulations!

[Valid RSS] This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

Source: https://thenewsthisweek.co.uk/feed/

  1. <?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
  2. xmlns:content="http://purl.org/rss/1.0/modules/content/"
  3. xmlns:wfw="http://wellformedweb.org/CommentAPI/"
  4. xmlns:dc="http://purl.org/dc/elements/1.1/"
  5. xmlns:atom="http://www.w3.org/2005/Atom"
  6. xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
  7. xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
  8. >
  9.  
  10. <channel>
  11. <title>Realizing the Open Data Center Ecosystem Vision | The News This Week</title>
  12. <atom:link href="https://thenewsthisweek.co.uk/feed/" rel="self" type="application/rss+xml" />
  13. <link>https://thenewsthisweek.co.uk</link>
  14. <description></description>
  15. <lastBuildDate>Mon, 13 Oct 2025 23:50:00 +0000</lastBuildDate>
  16. <language>en-GB</language>
  17. <sy:updatePeriod>
  18. hourly </sy:updatePeriod>
  19. <sy:updateFrequency>
  20. 1 </sy:updateFrequency>
  21. <generator>https://wordpress.org/?v=6.8.3</generator>
  22.  
  23. <image>
  24. <url>https://thenewsthisweek.co.uk/wp-content/uploads/2023/07/cropped-TNTW-logo-2-32x32.png</url>
  25. <title>Realizing the Open Data Center Ecosystem Vision | The News This Week</title>
  26. <link>https://thenewsthisweek.co.uk</link>
  27. <width>32</width>
  28. <height>32</height>
  29. </image>
  30. <item>
  31. <title>Realizing the Open Data Center Ecosystem Vision</title>
  32. <link>https://thenewsthisweek.co.uk/realizing-the-open-data-center-ecosystem-vision-27219/</link>
  34. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  35. <pubDate>Mon, 13 Oct 2025 23:50:00 +0000</pubDate>
  36. <category><![CDATA[Brand Post]]></category>
  37. <guid isPermaLink="false">https://thenewsthisweek.co.uk/realizing-the-open-data-center-ecosystem-vision-27219/</guid>
  38.  
  39. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="58" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/realizing-the-open-data-center-ecosystem-vision.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Realizing the Open Data Center Ecosystem Vision" decoding="async" /></div>OCP Launches New &#8220;Open Data Center for AI&#8221; Strategic Initiative SAN JOSE, Calif., Oct. 14, 2025 /PRNewswire/ &#8212; Today, the Open Compute Project Foundation (OCP), the nonprofit international organization bringing at-scale innovations and hyperscale best practices to all, announces an expansion to its Open Systems for AI, an umbrella initiative with the new Open Data Center [&#8230;]]]></description>
  40. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="58" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/realizing-the-open-data-center-ecosystem-vision.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Realizing the Open Data Center Ecosystem Vision" decoding="async" /></div><p class="prntac">
  41.                  <i>OCP Launches New &#8220;Open Data Center for AI&#8221; Strategic Initiative</i>
  42.                </p>
  43. <p>
  44.                  <span class="legendSpanClass">SAN JOSE, Calif.</span>, <span class="legendSpanClass">Oct. 14, 2025</span> /PRNewswire/ &#8212; Today, the Open Compute Project Foundation (OCP), the nonprofit international organization bringing at-scale innovations and hyperscale best practices to all, announces an expansion to its <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=16096476&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fprojects%2Fopen-systems-for-ai&amp;a=Open+Systems+for+AI" target="_blank" rel="nofollow">Open Systems for AI</a>, an umbrella initiative with the new Open Data Center for AI Strategic Initiative (SI), to increase efforts on key data center infrastructure challenges: power, cooling, mechanical, and management telemetry. The addition of this new strategic initiative is in response to a large increase in data center physical infrastructure projects and workstreams launched in the past year, learnings from the OCP Open Systems for AI SI <u><a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=3491783502&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fprojects%2Fopen-systems-for-ai%23workshops&amp;a=workshop+series" target="_blank" rel="nofollow">workshop series</a></u>, and the new <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=2013576874&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fabout%2Fa-call-for-collaboration-on-ai-data-center-infrastructure-standards&amp;a=open-letter+call+for+collaboration" target="_blank" rel="nofollow">open-letter call for collaboration</a>. With strong support from the OCP Board and stakeholders, the Foundation invites other organizations to sign this letter, which was initiated by Google, Meta, and Microsoft.. This underscores the OCP Foundation&#8217;s mission to support the entire open data center ecosystem, covering IT as well as physical data center infrastructure and facilities.</p>
  45. <div id="prni_dvprnejpg1355left" dir="ltr" style="width: 100%; text-align: left;">
  46.                  <img decoding="async" id="prnejpg1355left" title="Open Compute Project Foundation (OCP)" src="https://mma.prnewswire.com/media/1018821/OCP_Logo.jpg" alt="Open Compute Project Foundation (OCP)" align="middle"></img>
  47.                </div>
  48. <p>The mandate of the Open Data Center for AI SI is to develop standardizations for data center infrastructure allowing advanced high-density AI infrastructure to be deployed as flexibly as traditional compute where facilities are built with a common understanding of management telemetry, advanced power and cooling technologies to enable simpler deployment of a wide variety of AI solutions. The issue faced by data center partners including hyperscalers, neoclouds, co-location providers, enterprise users, and technology providers is that siloed efforts produce competing design requirements that slows innovations and extends deployment timelines. The goal is to identify and specify requirements for AI data centers such that the physical infrastructure common ground enables fungibility for a diverse AI IT infrastructure, especially while aspects of the AI IT elements are rapidly evolving. This will enable colocation data center providers to support a wider range of tenants with fewer customizations. </p>
  49. <p>&#8220;The OCP Community&#8217;s vision of the open data center ecosystem continues to enable solving the challenges of building at-scale AI clusters and the infrastructure that houses them. We are continuing to utilize OCP&#8217;s open, collaborative, and unique value proposition and its large community and ecosystem to develop open specifications and standards that address the bottlenecks that threaten to constrain the future of AI growth. We firmly believe OCP&#8217;s role in fostering development of open, standardized, sustainable, and scalable infrastructure to be increasingly vital to the industry and its supply chain enabling it to deliver on AI&#8217;s transformative potential cost effectively and with faster TTM, while managing its environmental impact,&#8221; said George Tchaparian, CEO at the Open Compute Project Foundation.</p>
  50. <p>The Open Data Center for AI SI will be able to build on several work efforts already underway within the OCP Community</p>
  51. <ul type="disc">
  52. <li>The new <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=3202380068&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fprojects%2Fcoolant-distribution-unit&amp;a=Coolant+Distribution+Unit" target="_blank" rel="nofollow">Coolant Distribution Unit</a> (CDU) Project covering integration of facilities&#8217; technology cooling systems and facility water systems into IT rack liquid cooling</li>
  53. <li>a <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=2322945016&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fprojects%2Fpower-distribution&amp;a=facilities-level+Power+Distribution" target="_blank" rel="nofollow">facilities-level Power Distribution</a> Project covering transition to a Direct Current distribution architecture that support high-powered IT rack.</li>
  54. </ul>
  55. <p>Other notable and recent contributions include </p>
  56. <ul type="disc">
  57. <li>
  58.                    <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=2882675982&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fdocuments%2Focp-specification-diablo-400-v0p5p2-2025-05-30-pdf&amp;a=Mt+Diablo+(Diablo+400)" target="_blank" rel="nofollow">Mt Diablo (Diablo 400)</a> power-rack sidecar for powering AI clusters, co-authored by Google, Meta and Microsoft; <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=2959439111&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fdocuments%2Focp-specification-deschutes-final-2025-09-05-pdf&amp;a=Deschutes+Coolant+Distribution+Unit" target="_blank" rel="nofollow">Deschutes Coolant Distribution Unit</a> (CDU), authored by Google;</li>
  59. <li>
  60.                    <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=3271473935&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fdocuments%2Fclemente-compute-tray-ocp-specification-v1-pdf&amp;a=Clemente" target="_blank" rel="nofollow">Clemente</a>, for high-performance AI compute trays, authored by Meta;</li>
  61. <li>and <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=1168826950&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fdocuments%2Fhyperscale-cpu-ras-and-debug-requirements-specification-v0-5-2025-05-22-pdf&amp;a=Hyperscale+CPU+RAS+and+Debug+Requirements" target="_blank" rel="nofollow">Hyperscale CPU RAS and Debug Requirements</a> for standardized debug capabilities for CPUs in hyperscale environments, co-authored by AMD, Google and Microsoft.</li>
  62. </ul>
  63. <p>The Diablo specification by Google, Meta and Microsoft describes a disaggregated power rack, or sidecar rack, pushing power delivery from today&#8217;s 48 volts direct current (VDC) within the rack to either +/-400 VDC or 800VDC. The Diablo specification defines power solutions for high-density AI racks, enabling IT racks from 100 kilowatts up to 1 megawatt. More than simply increasing power delivery capacity, selecting 400 VDC as the nominal voltage leverages the supply chain established by electric vehicles, for greater economies of scale, proven quality, and more efficient manufacturing, by standardizing the electrical and mechanical interfaces.</p>
  64. <p>The Deschutes CDU is targeted to support ~2 MW heat loads, with hydraulic capacity targets of 500 GPM at 80-90 psi, which would be among the highest CDU thermal capacities available in the industry. It promises to enhance thermal management and operational efficiency. The specification will enable any CDU supplier in the industry to develop, manufacture and improve upon the design. The CDU is assembled from components that are sourced from multiple vendors that are widely known in the industry, allowing vendors to build and data center owners to be able purchase a CDU based on this specification. Beyond supply chain considerations, installation and maintenance procedures are shared to enable fast deployments of reliable equipment.</p>
  65. <p>The Clemente specification describes a 1RU tall compute tray which integrates two NVIDIA GB300 Host Processor Modules (HPM) into a form factor with peripherals that support Meta&#8217;s AI/ML training and inference use cases. It also represents a milestone of a first deployment of a design that uses OCP ORv3 HPR (in-progress specification contribution) with side car power racks. The platform includes both air cooled and liquid cooled components. CPU, GPU and switch will be liquid cooled, with the remaining components air cooled.</p>
  66. <p>OCP&#8217;s above Open Systems for AI efforts continue to solidify OCP as the premiere open organization accelerating deployment of AI data centers. These resources and more are collected on OCP&#8217;s newly opened <u><a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=797977199&amp;u=https%3A%2F%2Fwww.opencompute.org%2Fai-marketplace&amp;a=AI+portal+on+the+OCP+Marketplace" target="_blank" rel="nofollow">AI portal on the OCP Marketplace</a></u>, providing one location for AI cluster designers, builders and facility providers to find the latest available AI infrastructure products and reference material.</p>
  67. <p>&#8220;With the AI infrastructure market moving very fast, there is a risk of higher costs due to fragmentations. It is the right time for an organization like the OCP to be facilitating a community to determine commonalities in data center facilities and IT Infrastructure that can help accelerate the market for future generations of AI cluster deployments and data center facility builds,&#8221; said Alan Weckel, Founder and Technology Analyst, 650 Group.</p>
  68. <p>
  69.                  <b>About the Open Compute Project Foundation<br /></br></b>The Open Compute Project (OCP) brings at-scale innovations and hyperscaler best practices to all, spanning technology domains from the data center to the edge, and the technology stack from silicon, to systems, to site facilities and services. The international OCP Community is made up of organizations and people from hyperscale and tier-2 cloud data center operators, communications providers, colocation providers, diverse enterprises, and technology vendors. With the tenets of openness, impact, efficiency, scale and sustainability, the OCP engages and educates thousands of engineers every year. Across many projects and initiatives, the OCP Foundation and Community are meeting the market today and shaping the future.</p>
  70. <p>Learn more at: <u><a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=3652857052&amp;u=http%3A%2F%2Fwww.opencompute.org%2F&amp;a=www.opencompute.org" target="_blank" rel="nofollow">www.opencompute.org</a></u>.</p>
  71. <p>
  72.                  <b>Media Contact<br /></br></b>Dirk Van Slyke<br /></br>Open Compute Project Foundation<br /></br>Vice President, Chief Marketing Officer<br /></br><a href="mailto:dirkv@opencompute.org" target="_blank" rel="nofollow">dirkv@opencompute.org</a><br /></br>Mobile: +1 303-999-7398<br /></br>(Central Time Zone/CST/Austin, TX)</p>
  73. <p>Logo &#8211; <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531558-1&amp;h=939582793&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1018821%2FOCP_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1018821%2FOCP_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1018821/OCP_Logo.jpg</a></p>
  74. <p id="PURL">
  75.                  <img decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96620&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/realizing-the-open-data-center-ecosystem-vision-302582596.html" target="_blank">https://www.prnewswire.co.uk/news-releases/realizing-the-open-data-center-ecosystem-vision-302582596.html</a></p>
  76. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96620&amp;Transmission_Id=202510131920PR_NEWS_EURO_ND__EN96620&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  77. ]]></content:encoded>
  81. </item>
  82. <item>
  83. <title>The Bahamas Achieves Major Fiscal Progress, Strengthening its Position as a Stable and Sustainable Financial Partner</title>
  84. <link>https://thenewsthisweek.co.uk/the-bahamas-achieves-major-fiscal-progress-strengthening-its-position-as-a-stable-and-sustainable-financial-partner-27221/</link>
  86. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  87. <pubDate>Mon, 13 Oct 2025 23:22:00 +0000</pubDate>
  88. <category><![CDATA[Brand Post]]></category>
  89. <guid isPermaLink="false">https://thenewsthisweek.co.uk/the-bahamas-achieves-major-fiscal-progress-strengthening-its-position-as-a-stable-and-sustainable-financial-partner-27221/</guid>
  90.  
  91. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="121" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/the-bahamas-achieves-major-fiscal-progress-strengthening-its-position-as-a-stable-and-sustainable-financial-partner.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="The Bahamas Achieves Major Fiscal Progress, Strengthening its Position as a Stable and Sustainable Financial Partner" decoding="async" loading="lazy" /></div>NASSAU, The Bahamas, Oct. 14, 2025 /PRNewswire/ &#8212; The Office of the Prime Minister last week announced that The Bahamas achieved a significant fiscal milestone, recording a 0.5% fiscal deficit for the budget year ending June 30, 2025. This result falls squarely within the government&#8217;s target range of 0.3% to 0.7% and marks a dramatic [&#8230;]]]></description>
  92. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="121" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/the-bahamas-achieves-major-fiscal-progress-strengthening-its-position-as-a-stable-and-sustainable-financial-partner.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="The Bahamas Achieves Major Fiscal Progress, Strengthening its Position as a Stable and Sustainable Financial Partner" decoding="async" loading="lazy" /></div><p>
  93.                  <span class="legendSpanClass">NASSAU, The Bahamas</span>, <span class="legendSpanClass">Oct. 14, 2025</span> /PRNewswire/ &#8212; The Office of the Prime Minister last week announced that The Bahamas achieved a significant fiscal milestone, recording a <b>0.5% fiscal deficit</b> for the budget year ending June 30, 2025. This result falls squarely within the government&#8217;s target range of 0.3% to 0.7% and marks a dramatic improvement from the 13.7% deficit in 2021. These official numbers have been confirmed by the Ministry of Finance.</p>
  94. <div id="prni_dvprnejpg93daleft" dir="ltr" style="width: 100%; text-align: left;">
  95.                  <img decoding="async" id="prnejpg93daleft" title="Commonwealth of the Bahamas " src="https://mma.prnewswire.com/media/2795163/Commonwealth_of_the_Bahamas_Logo.jpg" alt="Commonwealth of the Bahamas " align="middle"></img>
  96.                </div>
  97. <p>Prime Minister Philip Davis KC, MP, described the achievement as a clear signal to international partners, investors, and the global community that The Bahamas is on a path of sustained economic stability and responsible governance.</p>
  98. <p>&#8220;Four years ago, The Bahamas faced one of the most challenging fiscal periods in its modern history. Today, we stand on solid ground. The disciplined choices we made to protect our economy are still delivering results – not only for Bahamians, but for those we invest, trade, and collaborate with,&#8221; said Prime Minister Davis.</p>
  99. <p>The Prime Minister emphasized that fiscal progress translates into tangible benefits for citizens and creates a more attractive environment for international engagement.</p>
  100. <p>&#8220;Every dollar we save on debt strengthens our capacity to invest in infrastructure, education, healthcare, and renewable energy. These are all areas that matter to our people and our global partners who are looking for sustainability, stability, and growth,&#8221; he noted.</p>
  101. <p>The Bahamas&#8217; improved fiscal position comes alongside a broader national strategy, and one that is focused on resilience and sustainable development. This illustrates how The Bahamas plans to partner with its international counterparts, as the same fiscal policy that drives commitment to creating opportunities for Bahamians also permeates out to the international landscape.</p>
  102. <p>This fiscal discipline has earned international validation, with S&amp;P Global Ratings recently upgrading The Bahamas&#8217; sovereign credit rating to &#8216;BB-&#8216; from &#8216;B+&#8217;, citing &#8216;strengthened economic performance&#8217; and &#8216;sound fiscal management.&#8217; The agency projects that debt will fall to 66.3% of GDP by the end of 2025, down from 77.8% in 2020, and noted that &#8216;refinancing risks have abated, given the government&#8217;s commitment to fiscal discipline.&#8217;</p>
  103. <p>Prime Minister Davis said that for partners in the United States, United Kingdom, and beyond, this progress means greater confidence in The Bahamas as a secure destination for investment, a dependable ally in trade, and a committed participant in global economic and environmental initiatives.</p>
  104. <p>With its strategic location, strong tourism sector, and growing financial services industry, The Bahamas continues to position itself as a reliable international partner, specifically for the US, UK, and other international markets seeking opportunities in the Caribbean.</p>
  105. <p>&#8220;This is what responsible leadership looks like. It is steady progress that improves lives, strengthens our economy, and builds confidence among our partners worldwide. We are building a better future, one decision at a time, and we&#8217;re doing it together,&#8221; concluded Prime Minister Davis.</p>
  106. <p>This material is being distributed by The Burson Group LLC on behalf of The Bahamas, Ministry of Economic Affairs. Additional information is available at the Department of Justice, Washington, DC.</p>
  107. <p>Logo &#8211; <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531796-1&amp;h=2272640045&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2795163%2FCommonwealth_of_the_Bahamas_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2795163%2FCommonwealth_of_the_Bahamas_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2795163/Commonwealth_of_the_Bahamas_Logo.jpg</a> </p>
  108. <p id="PURL">
  109.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96864&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/the-bahamas-achieves-major-fiscal-progress-strengthening-its-position-as-a-stable-and-sustainable-financial-partner-302582575.html" target="_blank">https://www.prnewswire.co.uk/news-releases/the-bahamas-achieves-major-fiscal-progress-strengthening-its-position-as-a-stable-and-sustainable-financial-partner-302582575.html</a></p>
  110. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96864&amp;Transmission_Id=202510131922PR_NEWS_EURO_ND__EN96864&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  111. ]]></content:encoded>
  115. </item>
  116. <item>
  117. <title>NABR Comment on IUCN Determination</title>
  118. <link>https://thenewsthisweek.co.uk/nabr-comment-on-iucn-determination-27223/</link>
  120. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  121. <pubDate>Mon, 13 Oct 2025 22:47:00 +0000</pubDate>
  122. <category><![CDATA[Brand Post]]></category>
  123. <guid isPermaLink="false">https://thenewsthisweek.co.uk/nabr-comment-on-iucn-determination-27223/</guid>
  124.  
  125. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="43" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/nabr-comment-on-iucn-determination.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="NABR Comment on IUCN Determination" decoding="async" loading="lazy" /></div>WASHINGTON, Oct. 13, 2025 /PRNewswire/ &#8212; The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the &#8220;Endangered&#8221; status determination for long-tailed macaque (&#8220;LTM&#8221;) monkeys (Macaca fascicularis). The latest issuance by the IUCN follows a 2023 petition filed by the National Association for Biomedical Research (NABR) challenging the [&#8230;]]]></description>
  126. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="43" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/nabr-comment-on-iucn-determination.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="NABR Comment on IUCN Determination" decoding="async" loading="lazy" /></div><p>
  127.                  <span class="legendSpanClass">WASHINGTON</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the &#8220;Endangered&#8221; status determination for long-tailed macaque (&#8220;LTM&#8221;) monkeys (<i>Macaca fascicularis</i>).</p>
  128. <div id="prni_dvprnejpgb44aleft" dir="ltr" style="width: 100%; text-align: left;">
  129.                  <img decoding="async" id="prnejpgb44aleft" title=" " src="https://mma.prnewswire.com/media/1138543/NABR_Logo_1.jpg" alt=" " align="middle"></img>
  130.                </div>
  131. <p>The latest issuance by the IUCN follows a 2023 petition filed by the National Association for Biomedical Research (NABR) challenging the IUCN status determination. NABR&#8217;s petition demonstrates that reviews by Hansen et. al., which the IUCN has used as the basis for its status determinations, misrepresent existing scientific data.<sup>1</sup> More information regarding the NABR petition is available online at <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=1380002298&amp;u=https%3A%2F%2Fwww.nabr.org%2F&amp;a=www.nabr.org" target="_blank" rel="nofollow">www.nabr.org</a>.</p>
  132. <p>A separate petition filed with the IUCN by Dr. Hank Jenkins asserts that the Hansen et al. authors possess conflicts of interest that require further investigation by the IUCN. It is unclear if such conflicts exist, or if the authors of the IUCN review possess conflicts requiring disclosure or recusal.</p>
  133. <p>On October 7, 2024, the U.S. Fish and Wildlife Service (&#8220;the Service&#8221;) rejected a petition filed by advocacy groups to list &#8220;LTM&#8221; monkeys under the Endangered Species Act (&#8220;ESA&#8221;). The petition contains the same information submitted to the IUCN which is the basis for the IUCN&#8217;s current assessment. In rejecting the petition, the Service stated &#8220;the petition did not present credible information to support impacts to populations or the species as a whole.&#8221; The full findings from the Service on the petition to list long-tailed macaques under the U.S. Endangered Species Act is published in the <i>Federal Register</i> and is located <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=488510283&amp;u=https%3A%2F%2Fwww.nabr.org%2Fview_file%2F4817%2F2841%2F0901%2FLTM_Petition.pdf&amp;a=here" target="_blank" rel="nofollow">here</a>: &#8220;<a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=3289322291&amp;u=https%3A%2F%2Fwww.nabr.org%2Fview_file%2F4817%2F2841%2F0901%2FLTM_Petition.pdf&amp;a=LTM_Petition.pdf" target="_blank" rel="nofollow">LTM_Petition.pdf</a>.&#8221; No government in the world considers &#8220;LTM&#8221; monkeys to be endangered. Peer-reviewed scientific publications demonstrate the latest IUCN determination, and information used in the determination, are flawed and unsupported.<sup>2</sup> </p>
  134. <p>&#8220;The NABR scientific review team is disappointed that the IUCN has failed to objectively consider scientific information that has been presented,&#8221; stated <b>Dr. Ray Hilborn</b>, a world-renowned scientist and member of NABR&#8217;s scientific review team. </p>
  135. <p>&#8220;The lack of data on trends in abundance, and misrepresentation of data that do exist, raise serious questions about the scientific process employed by the IUCN to reach this determination,&#8221; added Dr. Hilborn.</p>
  136. <p>&#8220;LTM&#8221; monkeys are used extensively throughout the world in biomedical research given their physiological and genetic similarities with human beings. Five of the 20 most used prescription drugs were developed with the help of long-tailed macaques. Research with &#8220;LTM&#8221; monkeys has been crucial for advances in regenerative medicine, immunology, cancer, vaccine development, and pharmacology, as well as development of the COVID-19 vaccine.<sup><sup>3</sup></sup> The National Institutes of Health (NIH) recently published a review confirming the importance of &#8220;LTM&#8221; monkeys in conducting biomedical research. </p>
  137. <p>&#8220;NABR is disappointed that in the face of overwhelming scientific evidence, the IUCN has bowed to pressure from animal activists to suggest the &#8216;LTM&#8217; monkey as at risk,&#8221; <b>said Matthew R. Bailey, president of NABR.</b> &#8220;Available scientific information clearly shows this species is not at risk and in fact is considered to be invasive in several countries. It is beyond comprehension that the IUCN claims the species is at risk while simultaneously claiming it is one of the world&#8217;s most invasive species. NABR will continue to educate policy makers and the public on these issues to protect public health and the integrity of the scientific process.&#8221;</p>
  138. <p>According to a publication entitled &#8220;100 of the World&#8217;s Worst Invasive Alien Species,&#8221; &#8220;LTM&#8221; monkeys are recognized by the IUCN to be an &#8220;invasive&#8221; species.<sup>4</sup></p>
  139. <p>The conservation status of &#8220;LTM&#8221; monkeys and PETA&#8217;s involvement in government programs was recently the subject of a <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=2968061976&amp;u=https%3A%2F%2Fnaturalresources.house.gov%2Fcalendar%2Feventsingle.aspx%3FEventID%3D416435&amp;a=U.S.+House+of+Representatives+Oversight+Committee+hearing" target="_blank" rel="nofollow">U.S. House of Representatives Oversight Committee hearing</a> in September 2024. Witnesses at this hearing testified that PETA and other animal advocacy groups have improperly attempted to influence government investigations of private parties and foreign governments for political reasons.</p>
  140. <p>
  141.                  <b>About the National Association for Biomedical Research<br /></br></b>Founded in 1979, NABR is the only 501(c)(6) non-profit association dedicated to sound public policy for the humane use of animals in biomedical research, education, and testing. Members include more than 340 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and animal health. Learn more about us at <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=1380002298&amp;u=https%3A%2F%2Fwww.nabr.org%2F&amp;a=www.nabr.org" target="_blank" rel="nofollow">www.nabr.org</a>. </p>
  142. <p>
  143.                  <sup>1</sup> <i>See </i>Hilborn, R., &amp; Smith, D. R. (2023). <i>Is the long</i><i>‐</i><i>tailed macaque at risk of extinction?</i> American Journal of Primatology, e23590. (Available at <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=524927452&amp;u=https%3A%2F%2Fdoi.org%2F10.1002%2Fajp.23590&amp;a=https%3A%2F%2Fdoi.org%2F10.1002%2Fajp.23590" target="_blank" rel="nofollow">https://doi.org/10.1002/ajp.23590</a>).</p>
  144. <p>
  145.                  <sup>2</sup> <i>See </i>Hilborn, R., &amp; M. Chaloupka (2025). <i>Estimating the abundance of widely distributed primates. </i>American Journal of Primatology (accepted for publication).</p>
  146. <p>
  147.                  <sup>3</sup> <i>See </i>Albrecht, L., E. Bishop, B. Jay, B. Lafloux, M. Minoves, C. Passaes (2021). <i>COVID-19 Research: Lessons from Non-Human Primate Models</i> (2021) doi: 10.3390/vaccines9080886 (available at <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=2703173614&amp;u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8402317%2F&amp;a=www.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8402317%2F" target="_blank" rel="nofollow">www.ncbi.nlm.nih.gov/pmc/articles/PMC8402317/</a>.</p>
  148. <p>
  149.                  <sup>4</sup> <i>See </i>IUCN<i>, 100 of the World&#8217;s Worst Invasive Alien Species</i> (available at <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=4069955921&amp;u=https%3A%2F%2Fwww.iucngisd.org%2F&amp;a=www.iucngisd.org" target="_blank" rel="nofollow">www.iucngisd.org</a>).</p>
  150. <p class="prntac">Contact: Eva Maciejewski<br /></br><a href="mailto:emaciejewski@nabr.org" target="_blank" rel="nofollow">emaciejewski@nabr.org</a><br /></br>(202) 967-8305</p>
  151. <p>Logo &#8211; <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531579-1&amp;h=3196087062&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1138543%2FNABR_Logo_1.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1138543%2FNABR_Logo_1.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1138543/NABR_Logo_1.jpg</a> </p>
  152. <p id="PURL">
  153.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96642&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/nabr-comment-on-iucn-determination-302582556.html" target="_blank">https://www.prnewswire.co.uk/news-releases/nabr-comment-on-iucn-determination-302582556.html</a></p>
  154. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96642&amp;Transmission_Id=202510131847PR_NEWS_EURO_ND__EN96642&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  155. ]]></content:encoded>
  159. </item>
  160. <item>
  161. <title>J&#038;T Express Q3 Parcel Volume Surges 23.1% YoY, Driven by 78.7% Growth in Southeast Asia and 47.9% in New Markets</title>
  162. <link>https://thenewsthisweek.co.uk/jt-express-q3-parcel-volume-surges-23-1-yoy-driven-by-78-7-growth-in-southeast-asia-and-47-9-in-new-markets-27225/</link>
  164. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  165. <pubDate>Mon, 13 Oct 2025 22:20:00 +0000</pubDate>
  166. <category><![CDATA[Brand Post]]></category>
  167. <guid isPermaLink="false">https://thenewsthisweek.co.uk/jt-express-q3-parcel-volume-surges-23-1-yoy-driven-by-78-7-growth-in-southeast-asia-and-47-9-in-new-markets-27225/</guid>
  168.  
  169. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="41" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/jt-express-q3-parcel-volume-surges-23-1-yoy-driven-by-78-7-growth-in-southeast-asia-and-47-9-in-new-markets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="J&amp;T Express Q3 Parcel Volume Surges 23.1% YoY, Driven by 78.7% Growth in Southeast Asia and 47.9% in New Markets" decoding="async" loading="lazy" /></div>HONG KONG, Oct. 13, 2025 /PRNewswire/ &#8212; J&#38;T Global Express Limited (&#8220;J&#38;T Express&#8221; or &#8220;J&#38;T&#8221; or &#8220;the Company&#8221;, stock code: 01519.HK), a global logistics service provider, announced its key operating data for the third quarter of 2025. As of 30 September 2025, the Company achieved a total parcel volume of approximately 7.68 billion, representing a [&#8230;]]]></description>
  170. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="41" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/jt-express-q3-parcel-volume-surges-23-1-yoy-driven-by-78-7-growth-in-southeast-asia-and-47-9-in-new-markets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="J&amp;T Express Q3 Parcel Volume Surges 23.1% YoY, Driven by 78.7% Growth in Southeast Asia and 47.9% in New Markets" decoding="async" loading="lazy" /></div><p>
  171.                  <span class="legendSpanClass">HONG KONG</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; <b>J&amp;T Global Express Limited (</b>&#8220;<b>J&amp;T Express</b>&#8221; or &#8220;<b>J&amp;T</b>&#8221; or &#8220;the Company&#8221;, stock code: <a href="https://01519.hk/" target="_blank" rel="nofollow">01519.HK</a>)<b>, </b>a global logistics service provider, announced its key operating data for the third quarter of 2025. As of 30 September 2025, the Company achieved a total parcel volume of approximately 7.68 billion, representing a 23.1% year-on-year (&#8220;YoY&#8221;) increase. Daily parcel volume averaged 83.4 million, with all major markets achieving double-digit growth, led by particularly robust expansion in Southeast Asia and New Markets.</p>
  172. <div id="prni_dvprnejpg84faleft" dir="ltr" style="width: 100%; text-align: left;">
  173.                  <img decoding="async" id="prnejpg84faleft" title=" " src="https://mma.prnewswire.com/media/1721319/JT_Express_Logo.jpg" alt=" " align="middle"></img>
  174.                </div>
  175. <p>As the leading express delivery company by market share in Southeast Asia, J&amp;T maintained strong growth momentum in the region during the third quarter，parcel volume in SEA reached 2.00 billion, surging 78.7% year-on-year, with an average daily parcel volume of 21.7 million. As of the end of September 2025, the number of outlets in SEA reached 10,700, an increase of 900 compared with the end of 2024. The rapid growth in parcel volume also drove a higher demand for line-haul capacity, with the number of line-haul vehicles in SEA rising to 5,500 in the third quarter, also up by 900 compared to the end of 2024.</p>
  176. <p>Amidst intense competition in China, parcel volume in China reached 5.58 billion in Q3 , maintaining a double-digit YoY growth of 10.4%, with an average daily parcel volume of 60.6 million. In New Markets (Saudi Arabia, the UAE, Mexico, Brazil, and Egypt), J&amp;T&#8217;s parcel volume reached 104 million in Q3, a YoY increase of 47.9%, with an average daily parcel volume of 1.13 million.</p>
  177. <p>Logo &#8211; <a href="https://mma.prnewswire.com/media/1721319/JT_Express_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1721319/JT_Express_Logo.jpg</a></p>
  178. <p id="PURL">
  179.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96526&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/jt-express-q3-parcel-volume-surges-23-1-yoy-driven-by-78-7-growth-in-southeast-asia-and-47-9-in-new-markets-302582412.html" target="_blank">https://www.prnewswire.co.uk/news-releases/jt-express-q3-parcel-volume-surges-23-1-yoy-driven-by-78-7-growth-in-southeast-asia-and-47-9-in-new-markets-302582412.html</a></p>
  180. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96526&amp;Transmission_Id=202510131820PR_NEWS_EURO_ND__EN96526&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  181. ]]></content:encoded>
  185. </item>
  186. <item>
  187. <title>Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements &#124; DelveInsight</title>
  188. <link>https://thenewsthisweek.co.uk/allergic-rhino-conjunctivitis-market-poised-for-significant-growth-in-the-coming-10-years-amid-increasing-therapeutic-advancements-delveinsight-27227/</link>
  190. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  191. <pubDate>Mon, 13 Oct 2025 21:31:00 +0000</pubDate>
  192. <category><![CDATA[Brand Post]]></category>
  193. <guid isPermaLink="false">https://thenewsthisweek.co.uk/allergic-rhino-conjunctivitis-market-poised-for-significant-growth-in-the-coming-10-years-amid-increasing-therapeutic-advancements-delveinsight-27227/</guid>
  194.  
  195. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="65" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/allergic-rhino-conjunctivitis-market-poised-for-significant-growth-in-the-coming-10-years-amid-increasing-therapeutic-advancements-delveinsight.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight" decoding="async" loading="lazy" /></div>The allergic rhino-conjunctivitis market is experiencing steady growth, driven by the rising prevalence of allergic conditions and increased awareness of effective management options. Advances in treatment, including allergen immunotherapy and targeted biologics, are expanding therapeutic choices and improving patient outcomes. Additionally, the ongoing research and development of novel therapies, such as Immunotek&#8217;s MM09, MG01 + [&#8230;]]]></description>
  196. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="65" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/allergic-rhino-conjunctivitis-market-poised-for-significant-growth-in-the-coming-10-years-amid-increasing-therapeutic-advancements-delveinsight.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight" decoding="async" loading="lazy" /></div><p>
  197.                  <b><br />
  198.                    <i>The allergic rhino-conjunctivitis market is experiencing steady growth, driven by the rising prevalence of allergic conditions and increased awareness of effective management options. Advances in treatment, including allergen immunotherapy and targeted biologics, are expanding therapeutic choices and improving patient outcomes. Additionally, the ongoing research and development of novel therapies, such as Immunotek&#8217;s MM09, MG01 + T517, and MG56, are expected to sustain long-term market expansion.</i><br />
  199.                  </b>
  200.                </p>
  201. <p>
  202.                  <span class="legendSpanClass">LAS VEGAS</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; DelveInsight&#8217;s <b><u><a href="https://www.delveinsight.com/report-store/allergic-rhino-conjunctivitis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Allergic Rhino-Conjunctivitis Market Insights</a></u></b> report includes a comprehensive understanding of current treatment practices, allergic rhino-conjunctivitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). </p>
  203. <div id="prni_dvprnejpgf12bleft" dir="ltr" style="width: 100%; text-align: left;">
  204.                  <img decoding="async" id="prnejpgf12bleft" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle"></img>
  205.                </div>
  206. <p>
  207.                  <b>Allergic Rhino-Conjunctivitis Market Summary</b>
  208.                </p>
  209. <ul type="disc">
  210. <li>The market size for allergic rhino-conjunctivitis in the leading markets is expected to grow significantly by 2034.</li>
  211. <li>The United States accounted for the highest allergic rhino-conjunctivitis treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.</li>
  212. <li>Allergic rhino-conjunctivitis, a common chronic inflammatory condition encompassing both allergic rhinitis and allergic conjunctivitis, affects approximately <b>20%</b> of the global population.</li>
  213. <li>Leading allergic rhino-conjunctivitis companies, such as <b>Immunotek, Merck, ALK-Abello,</b> and others, are active in the allergic rhino-conjunctivitis market. </li>
  214. <li>The promising allergic rhino-conjunctivitis therapies in clinical trials include <b>MM09, MG01 + T517, MG56, </b>and others.</li>
  215. </ul>
  216. <p>Discover the allergic rhino-conjunctivitis new treatment @ <b><u><a href="https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">New Treatments for Allergic Rhino-Conjunctivitis</a></u></b></p>
  217. <p>
  218.                  <b>Key Factors Driving the Growth of the Allergic Rhino-Conjunctivitis Market </b>
  219.                </p>
  220. <p>
  221.                  <b>Rising Prevalence of Allergic Conditions</b>
  222.                </p>
  223. <p>The global incidence of allergic rhinitis and conjunctivitis is on the rise, influenced by factors such as increased pollution, urbanization, and environmental allergens. These conditions are now more prevalent in both adults and children, leading to a higher demand for effective treatments.</p>
  224. <p>
  225.                  <b>Technological Integration in Treatment Delivery</b>
  226.                </p>
  227. <p>Innovations in drug delivery systems, such as advanced nasal sprays and ophthalmic formulations, have improved the efficacy and convenience of ARC treatments. These technological advancements enhance patient compliance and satisfaction.</p>
  228. <p>
  229.                  <b>Emergence of Novel Allergic Rhino-Conjunctivitis Drugs</b>
  230.                </p>
  231. <p>The allergic rhino-conjunctivitis clinical trial landscape is not very robust; only a few drugs are included, such as <b>Immunotek&#8217;s MM09, MG01 + T517, and MG56</b>, among others. </p>
  232. <p>
  233.                  <b>Allergic Rhino-Conjunctivitis Market Analysis</b>
  234.                </p>
  235. <p>For many patients suffering from allergic rhino-conjunctivitis, allergen immunotherapy (AIT) continues to be the standard treatment. While numerous studies have shown that AIT improves symptom control and overall quality of life compared to placebo, new therapeutic approaches are now exploring targeted biologics, including monoclonal antibodies, which offer greater treatment precision and efficacy.</p>
  236. <p>Within the limited pipeline, Immunotek is the most active player, with ongoing trials listed on ClinicalTrials.gov, despite a lack of recent updates on its website or official pipeline disclosures. <b>Blueprint Medicines</b> is also evaluating<b> BLU-808</b> for allergic rhino-conjunctivitis in Canada; however, the company&#8217;s current focus on securing regulatory approval for BLU-808 in Chronic Spontaneous Urticaria (CSU) in the US suggests that a US Investigational New Drug (IND) filing for allergic rhino-conjunctivitis may follow.</p>
  237. <p>Overall, the relatively sparse pipeline for allergic rhino-conjunctivitis indicates significant potential for innovation and market entry. As new therapies gradually emerge, the treatment landscape is expected to shift, creating opportunities for companies to address the substantial unmet medical need—especially given the high rate of treatment switching and reliance on multi-drug regimens. Physicians&#8217; interest in more effective novel therapies is likely to drive demand further, making this a strategically attractive area for pipeline development and investment.</p>
  238. <p>To know more about allergic rhino-conjunctivitis treatment options, visit @ <b><u><a href="https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Approved Allergic Rhino-Conjunctivitis Drugs</a></u></b></p>
  239. <p>
  240.                  <b>Allergic Rhino-Conjunctivitis Competitive Landscape</b>
  241.                </p>
  242. <p>The emerging drug pipeline for allergic rhino-conjunctivitis is not very robust; only a few drugs are included, such as <b>Immunotek&#8217;s MM09, MG01 + T517, and MG56</b>, among others. </p>
  243. <p>
  244.                  <b>Immunotek </b>is actively conducting multiple trials involving <b>MM09</b>, a purified allergenic extract. MM09 is adsorbed onto aluminum hydroxide and polymerized with glutaraldehyde, combining a mite mixture of <i>Dermatophagoides pteronyssinus</i> and <i>Dermatophagoides farinae</i>, for the treatment of mild to moderate asthma and rhinitis/rhino-conjunctivitis. Administered subcutaneously, MM09 consists of allergoid-mannan conjugates. The company is currently planning a Phase III clinical trial (NCT05400811), which is not yet recruiting, to assess the efficacy and safety of this therapy for HDM-induced allergic asthma and rhinitis/rhino-conjunctivitis.</p>
  245. <p>Additionally, Immunotek has previously initiated another Phase III trial (NCT04435990) to evaluate the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis, with or without asthma, who are sensitized to <i>Dermatophagoides pteronyssinus</i> and/or <i>Dermatophagoides farinae</i>.</p>
  246. <p>
  247.                  <b>Immunotek </b>is also developing <b>MG56</b>, an immunotherapy for allergic rhinitis caused by grass pollens. This product contains allergen extracts from <i>Phleum</i> (timothy grass) and <i>Dactylis</i> pollens. It has progressed through clinical trials, including a Phase III study, to establish its efficacy and safety for patients with grass pollen-induced allergic rhinitis.</p>
  248. <p>The anticipated launch of these emerging therapies are poised to transform the allergic rhino-conjunctivitis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the allergic rhino-conjunctivitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.</p>
  249. <p>Discover more about therapy for allergic rhino-conjunctivitis @ <b><u><a href="https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Allergic Rhino-Conjunctivitis Clinical Trials </a></u></b></p>
  250. <p>
  251.                  <b>What is Allergic Rhino-Conjunctivitis?</b>
  252.                </p>
  253. <p>Allergic rhino-conjunctivitis is an inflammatory condition triggered by allergens. It arises from an IgE-mediated immune response, leading to inflammation of the nasal mucosa. IgE antibodies are produced in lymphoid tissues as well as locally in response to common environmental allergens. When these allergens bind to IgE on mast cells, they trigger the degranulation of mast cells and the release of numerous biochemical mediators. Histamine plays a central role in the acute allergic reaction. The condition commonly presents as either seasonal allergic rhino-conjunctivitis (SAR) or perennial allergic rhino-conjunctivitis (PAR). While histamine is a primary mediator responsible for SAR symptoms, other mediators such as leukotrienes and prostaglandin D2 also contribute.</p>
  254. <p>
  255.                  <b>Allergic Rhino-Conjunctivitis Epidemiology Segmentation</b>
  256.                </p>
  257. <p>The allergic rhino-conjunctivitis epidemiology section provides insights into the historical and current allergic rhino-conjunctivitis patient pool and forecasted trends for the leading markets. According to our secondary research, it was estimated that the prevalence of rhino-conjunctivitis symptoms was <b>14.6% </b>among 13–14-year-olds (range, 1–45.1%), and for 6–7-year-old patients, the prevalence was <b>8.5%</b>, along with a wide geographic variation.</p>
  258. <p>The allergic rhino-conjunctivitis market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:</p>
  259. <ul type="disc">
  260. <li>Total Prevalent Cases of Allergic Rhino-Conjunctivitis</li>
  261. <li>Diagnosed Prevalent Cases of Allergic Rhino-Conjunctivitis</li>
  262. <li>Age-specific Cases of Allergic Rhino-Conjunctivitis</li>
  263. <li>Treatable Cases of Allergic Rhino-Conjunctivitis</li>
  264. </ul>
  265. <div>
  266. <table border="0" cellspacing="0" cellpadding="1" class="prnbcc">
  267. <tr>
  268. <td class="prngen2" colspan="1" rowspan="1">
  269. <p class="prnml4">
  270.                          <span class="prnews_span"><br />
  271.                            <b>Allergic Rhino-Conjunctivitis Market Report Metrics</b><br />
  272.                          </span>
  273.                        </p>
  274. </td>
  275. <td class="prngen3" colspan="1" rowspan="1">
  276. <p class="prnml4">
  277.                          <span class="prnews_span"><br />
  278.                            <b>Details</b><br />
  279.                          </span>
  280.                        </p>
  281. </td>
  282. </tr>
  283. <tr>
  284. <td class="prngen4" colspan="1" rowspan="1">
  285. <p class="prnml4">
  286.                          <span class="prnews_span">Study Period</span>
  287.                        </p>
  288. </td>
  289. <td class="prngen5" colspan="1" rowspan="1">
  290. <p class="prnml4">
  291.                          <span class="prnews_span">2020–2034</span>
  292.                        </p>
  293. </td>
  294. </tr>
  295. <tr>
  296. <td class="prngen4" colspan="1" rowspan="1">
  297. <p class="prnml4">
  298.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market Report Coverage</span>
  299.                        </p>
  300. </td>
  301. <td class="prngen5" colspan="1" rowspan="1">
  302. <p class="prnml4">
  303.                          <span class="prnews_span">7MM [The United States, the EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan].</span>
  304.                        </p>
  305. </td>
  306. </tr>
  307. <tr>
  308. <td class="prngen4" colspan="1" rowspan="1">
  309. <p class="prnml4">
  310.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Epidemiology Segmentation</span>
  311.                        </p>
  312. </td>
  313. <td class="prngen5" colspan="1" rowspan="1">
  314. <p class="prnml4">
  315.                          <span class="prnews_span">Total Prevalent Cases of Allergic Rhino-Conjunctivitis, Diagnosed Prevalent Cases of Allergic Rhino-Conjunctivitis, Age-specific Cases of Allergic Rhino-Conjunctivitis, and Treatable Cases of Allergic Rhino-Conjunctivitis</span>
  316.                        </p>
  317. </td>
  318. </tr>
  319. <tr>
  320. <td class="prngen4" colspan="1" rowspan="1">
  321. <p class="prnml4">
  322.                          <span class="prnews_span">Key Allergic Rhino-Conjunctivitis Companies</span>
  323.                        </p>
  324. </td>
  325. <td class="prngen5" colspan="1" rowspan="1">
  326. <p class="prnml4">
  327.                          <span class="prnews_span">Immunotek, Merck, ALK-Abello, and others</span>
  328.                        </p>
  329. </td>
  330. </tr>
  331. <tr>
  332. <td class="prngen4" colspan="1" rowspan="1">
  333. <p class="prnml4">
  334.                          <span class="prnews_span">Key Allergic Rhino-Conjunctivitis Therapies</span>
  335.                        </p>
  336. </td>
  337. <td class="prngen5" colspan="1" rowspan="1">
  338. <p class="prnml4">
  339.                          <span class="prnews_span">MM09, MG01 + T517, MG56, GRASTEK, RAGWITEK, ODACTRA, and others</span>
  340.                        </p>
  341. </td>
  342. </tr>
  343. </table></div>
  344. <p>
  345.                  <b>Scope of the </b><br />
  346.                  <b>Allergic Rhino-Conjunctivitis</b><br />
  347.                  <b> Market Report</b>
  348.                </p>
  349. <ul type="disc">
  350. <li>
  351.                    <b>Therapeutic Assessment: </b>Allergic Rhino-Conjunctivitis current marketed and emerging therapies</li>
  352. <li>
  353.                    <b>Allergic Rhino-Conjunctivitis</b> <b>Market Dynamics:</b> Key Market Forecast Assumptions of Emerging Allergic Rhino-Conjunctivitis Drugs and Market Outlook</li>
  354. <li>
  355.                    <b>Competitive Intelligence Analysis:</b> SWOT analysis and Market entry strategies</li>
  356. <li>
  357.                    <b>Unmet Needs, KOL&#8217;s views, Analyst&#8217;s views, Allergic Rhino-Conjunctivitis Market Access and Reimbursement</b>
  358.                  </li>
  359. </ul>
  360. <p>Download the report to understand which factors are driving allergic rhino-conjunctivitis therapeutics market trends @ <b><u><a href="https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Allergic Rhino-Conjunctivitis Market Trends</a></u></b></p>
  361. <p>
  362.                  <b>Table of Contents</b>
  363.                </p>
  364. <div>
  365. <table border="0" cellspacing="0" cellpadding="1" class="prnbcc">
  366. <tr>
  367. <td class="prngen2" colspan="1" rowspan="1">
  368. <p class="prnml4">
  369.                          <span class="prnews_span">1</span>
  370.                        </p>
  371. </td>
  372. <td class="prngen3" colspan="1" rowspan="1">
  373. <p class="prnml4">
  374.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market Key Insights</span>
  375.                        </p>
  376. </td>
  377. </tr>
  378. <tr>
  379. <td class="prngen4" colspan="1" rowspan="1">
  380. <p class="prnml4">
  381.                          <span class="prnews_span">2</span>
  382.                        </p>
  383. </td>
  384. <td class="prngen5" colspan="1" rowspan="1">
  385. <p class="prnml4">
  386.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market Report Introduction</span>
  387.                        </p>
  388. </td>
  389. </tr>
  390. <tr>
  391. <td class="prngen4" colspan="1" rowspan="1">
  392. <p class="prnml4">
  393.                          <span class="prnews_span">3</span>
  394.                        </p>
  395. </td>
  396. <td class="prngen5" colspan="1" rowspan="1">
  397. <p class="prnml4">
  398.                          <span class="prnews_span">Executive Summary of Allergic Rhino-Conjunctivitis</span>
  399.                        </p>
  400. </td>
  401. </tr>
  402. <tr>
  403. <td class="prngen4" colspan="1" rowspan="1">
  404. <p class="prnml4">
  405.                          <span class="prnews_span">4</span>
  406.                        </p>
  407. </td>
  408. <td class="prngen5" colspan="1" rowspan="1">
  409. <p class="prnml4">
  410.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market Overview at a Glance</span>
  411.                        </p>
  412. </td>
  413. </tr>
  414. <tr>
  415. <td class="prngen4" colspan="1" rowspan="1">
  416. <p class="prnml4">
  417.                          <span class="prnews_span">4.1</span>
  418.                        </p>
  419. </td>
  420. <td class="prngen5" colspan="1" rowspan="1">
  421. <p class="prnml4">
  422.                          <span class="prnews_span">Market Share Distribution (%) by Therapies in 2024 in the 7MM</span>
  423.                        </p>
  424. </td>
  425. </tr>
  426. <tr>
  427. <td class="prngen4" colspan="1" rowspan="1">
  428. <p class="prnml4">
  429.                          <span class="prnews_span">4.2</span>
  430.                        </p>
  431. </td>
  432. <td class="prngen5" colspan="1" rowspan="1">
  433. <p class="prnml4">
  434.                          <span class="prnews_span">Market Share Distribution (%) by Therapies in 2034 in the 7MM</span>
  435.                        </p>
  436. </td>
  437. </tr>
  438. <tr>
  439. <td class="prngen4" colspan="1" rowspan="1">
  440. <p class="prnml4">
  441.                          <span class="prnews_span">5</span>
  442.                        </p>
  443. </td>
  444. <td class="prngen5" colspan="1" rowspan="1">
  445. <p class="prnml4">
  446.                          <span class="prnews_span">Key Events</span>
  447.                        </p>
  448. </td>
  449. </tr>
  450. <tr>
  451. <td class="prngen4" colspan="1" rowspan="1">
  452. <p class="prnml4">
  453.                          <span class="prnews_span">6</span>
  454.                        </p>
  455. </td>
  456. <td class="prngen5" colspan="1" rowspan="1">
  457. <p class="prnml4">
  458.                          <span class="prnews_span">Epidemiology and Market Methodology of Allergic Rhino-Conjunctivitis</span>
  459.                        </p>
  460. </td>
  461. </tr>
  462. <tr>
  463. <td class="prngen4" colspan="1" rowspan="1">
  464. <p class="prnml4">
  465.                          <span class="prnews_span">7</span>
  466.                        </p>
  467. </td>
  468. <td class="prngen5" colspan="1" rowspan="1">
  469. <p class="prnml4">
  470.                          <span class="prnews_span">Disease Background and Overview of Allergic Rhino-Conjunctivitis</span>
  471.                        </p>
  472. </td>
  473. </tr>
  474. <tr>
  475. <td class="prngen4" colspan="1" rowspan="1">
  476. <p class="prnml4">
  477.                          <span class="prnews_span">7.1</span>
  478.                        </p>
  479. </td>
  480. <td class="prngen5" colspan="1" rowspan="1">
  481. <p class="prnml4">
  482.                          <span class="prnews_span">Introduction</span>
  483.                        </p>
  484. </td>
  485. </tr>
  486. <tr>
  487. <td class="prngen4" colspan="1" rowspan="1">
  488. <p class="prnml4">
  489.                          <span class="prnews_span">7.2</span>
  490.                        </p>
  491. </td>
  492. <td class="prngen5" colspan="1" rowspan="1">
  493. <p class="prnml4">
  494.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Signs and Symptoms</span>
  495.                        </p>
  496. </td>
  497. </tr>
  498. <tr>
  499. <td class="prngen4" colspan="1" rowspan="1">
  500. <p class="prnml4">
  501.                          <span class="prnews_span">7.3</span>
  502.                        </p>
  503. </td>
  504. <td class="prngen5" colspan="1" rowspan="1">
  505. <p class="prnml4">
  506.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Classification</span>
  507.                        </p>
  508. </td>
  509. </tr>
  510. <tr>
  511. <td class="prngen4" colspan="1" rowspan="1">
  512. <p class="prnml4">
  513.                          <span class="prnews_span">7.4</span>
  514.                        </p>
  515. </td>
  516. <td class="prngen5" colspan="1" rowspan="1">
  517. <p class="prnml4">
  518.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Risk Factors</span>
  519.                        </p>
  520. </td>
  521. </tr>
  522. <tr>
  523. <td class="prngen4" colspan="1" rowspan="1">
  524. <p class="prnml4">
  525.                          <span class="prnews_span">7.5</span>
  526.                        </p>
  527. </td>
  528. <td class="prngen5" colspan="1" rowspan="1">
  529. <p class="prnml4">
  530.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Diagnosis</span>
  531.                        </p>
  532. </td>
  533. </tr>
  534. <tr>
  535. <td class="prngen4" colspan="1" rowspan="1">
  536. <p class="prnml4">
  537.                          <span class="prnews_span">8</span>
  538.                        </p>
  539. </td>
  540. <td class="prngen5" colspan="1" rowspan="1">
  541. <p class="prnml4">
  542.                          <span class="prnews_span">Treatment of Allergic Rhino-Conjunctivitis</span>
  543.                        </p>
  544. </td>
  545. </tr>
  546. <tr>
  547. <td class="prngen4" colspan="1" rowspan="1">
  548. <p class="prnml4">
  549.                          <span class="prnews_span">9</span>
  550.                        </p>
  551. </td>
  552. <td class="prngen5" colspan="1" rowspan="1">
  553. <p class="prnml4">
  554.                          <span class="prnews_span">Epidemiology and Patient Population: The 7MM Analysis of Allergic Rhino-Conjunctivitis</span>
  555.                        </p>
  556. </td>
  557. </tr>
  558. <tr>
  559. <td class="prngen4" colspan="1" rowspan="1">
  560. <p class="prnml4">
  561.                          <span class="prnews_span">9.1</span>
  562.                        </p>
  563. </td>
  564. <td class="prngen5" colspan="1" rowspan="1">
  565. <p class="prnml4">
  566.                          <span class="prnews_span">Key Findings</span>
  567.                        </p>
  568. </td>
  569. </tr>
  570. <tr>
  571. <td class="prngen4" colspan="1" rowspan="1">
  572. <p class="prnml4">
  573.                          <span class="prnews_span">9.2</span>
  574.                        </p>
  575. </td>
  576. <td class="prngen5" colspan="1" rowspan="1">
  577. <p class="prnml4">
  578.                          <span class="prnews_span">Assumptions and Rationale</span>
  579.                        </p>
  580. </td>
  581. </tr>
  582. <tr>
  583. <td class="prngen4" colspan="1" rowspan="1">
  584. <p class="prnml4">
  585.                          <span class="prnews_span">9.3</span>
  586.                        </p>
  587. </td>
  588. <td class="prngen5" colspan="1" rowspan="1">
  589. <p class="prnml4">
  590.                          <span class="prnews_span">Total Prevalent Cases of Allergic Rhino-Conjunctivitis in the 7MM</span>
  591.                        </p>
  592. </td>
  593. </tr>
  594. <tr>
  595. <td class="prngen4" colspan="1" rowspan="1">
  596. <p class="prnml4">
  597.                          <span class="prnews_span">9.4</span>
  598.                        </p>
  599. </td>
  600. <td class="prngen5" colspan="1" rowspan="1">
  601. <p class="prnml4">
  602.                          <span class="prnews_span">The United States</span>
  603.                        </p>
  604. </td>
  605. </tr>
  606. <tr>
  607. <td class="prngen4" colspan="1" rowspan="1">
  608. <p class="prnml4">
  609.                          <span class="prnews_span">9.4.1</span>
  610.                        </p>
  611. </td>
  612. <td class="prngen5" colspan="1" rowspan="1">
  613. <p class="prnml4">
  614.                          <span class="prnews_span">Total Prevalent Cases of Allergic Rhino-Conjunctivitis in the United States</span>
  615.                        </p>
  616. </td>
  617. </tr>
  618. <tr>
  619. <td class="prngen4" colspan="1" rowspan="1">
  620. <p class="prnml4">
  621.                          <span class="prnews_span">9.4.2</span>
  622.                        </p>
  623. </td>
  624. <td class="prngen5" colspan="1" rowspan="1">
  625. <p class="prnml4">
  626.                          <span class="prnews_span">Diagnosed Prevalent Cases of Allergic Rhino-Conjunctivitis in the United States</span>
  627.                        </p>
  628. </td>
  629. </tr>
  630. <tr>
  631. <td class="prngen4" colspan="1" rowspan="1">
  632. <p class="prnml4">
  633.                          <span class="prnews_span">9.4.3</span>
  634.                        </p>
  635. </td>
  636. <td class="prngen5" colspan="1" rowspan="1">
  637. <p class="prnml4">
  638.                          <span class="prnews_span">Age-specific Cases of Allergic Rhino-Conjunctivitis in the United States</span>
  639.                        </p>
  640. </td>
  641. </tr>
  642. <tr>
  643. <td class="prngen4" colspan="1" rowspan="1">
  644. <p class="prnml4">
  645.                          <span class="prnews_span">9.4.4</span>
  646.                        </p>
  647. </td>
  648. <td class="prngen5" colspan="1" rowspan="1">
  649. <p class="prnml4">
  650.                          <span class="prnews_span">Treatable Cases of Allergic Rhino-Conjunctivitis in the United States</span>
  651.                        </p>
  652. </td>
  653. </tr>
  654. <tr>
  655. <td class="prngen4" colspan="1" rowspan="1">
  656. <p class="prnml4">
  657.                          <span class="prnews_span">9.5</span>
  658.                        </p>
  659. </td>
  660. <td class="prngen5" colspan="1" rowspan="1">
  661. <p class="prnml4">
  662.                          <span class="prnews_span">EU4 and the UK</span>
  663.                        </p>
  664. </td>
  665. </tr>
  666. <tr>
  667. <td class="prngen4" colspan="1" rowspan="1">
  668. <p class="prnml4">
  669.                          <span class="prnews_span">9.6</span>
  670.                        </p>
  671. </td>
  672. <td class="prngen5" colspan="1" rowspan="1">
  673. <p class="prnml4">
  674.                          <span class="prnews_span">Japan</span>
  675.                        </p>
  676. </td>
  677. </tr>
  678. <tr>
  679. <td class="prngen4" colspan="1" rowspan="1">
  680. <p class="prnml4">
  681.                          <span class="prnews_span">10</span>
  682.                        </p>
  683. </td>
  684. <td class="prngen5" colspan="1" rowspan="1">
  685. <p class="prnml4">
  686.                          <span class="prnews_span">Patient Journey of Allergic Rhino-Conjunctivitis</span>
  687.                        </p>
  688. </td>
  689. </tr>
  690. <tr>
  691. <td class="prngen4" colspan="1" rowspan="1">
  692. <p class="prnml4">
  693.                          <span class="prnews_span">11</span>
  694.                        </p>
  695. </td>
  696. <td class="prngen5" colspan="1" rowspan="1">
  697. <p class="prnml4">
  698.                          <span class="prnews_span">Marketed Drugs for Allergic Rhino-Conjunctivitis</span>
  699.                        </p>
  700. </td>
  701. </tr>
  702. <tr>
  703. <td class="prngen4" colspan="1" rowspan="1">
  704. <p class="prnml4">
  705.                          <span class="prnews_span">11.1</span>
  706.                        </p>
  707. </td>
  708. <td class="prngen5" colspan="1" rowspan="1">
  709. <p class="prnml4">
  710.                          <span class="prnews_span">Key Competitors</span>
  711.                        </p>
  712. </td>
  713. </tr>
  714. <tr>
  715. <td class="prngen4" colspan="1" rowspan="1">
  716. <p class="prnml4">
  717.                          <span class="prnews_span">11.2</span>
  718.                        </p>
  719. </td>
  720. <td class="prngen5" colspan="1" rowspan="1">
  721. <p class="prnml4">
  722.                          <span class="prnews_span">ODACTRA: ALK-Abello</span>
  723.                        </p>
  724. </td>
  725. </tr>
  726. <tr>
  727. <td class="prngen4" colspan="1" rowspan="1">
  728. <p class="prnml4">
  729.                          <span class="prnews_span">11.2.1</span>
  730.                        </p>
  731. </td>
  732. <td class="prngen5" colspan="1" rowspan="1">
  733. <p class="prnml4">
  734.                          <span class="prnews_span">Product Description</span>
  735.                        </p>
  736. </td>
  737. </tr>
  738. <tr>
  739. <td class="prngen4" colspan="1" rowspan="1">
  740. <p class="prnml4">
  741.                          <span class="prnews_span">11.2.2</span>
  742.                        </p>
  743. </td>
  744. <td class="prngen5" colspan="1" rowspan="1">
  745. <p class="prnml4">
  746.                          <span class="prnews_span">Regulatory Milestones</span>
  747.                        </p>
  748. </td>
  749. </tr>
  750. <tr>
  751. <td class="prngen4" colspan="1" rowspan="1">
  752. <p class="prnml4">
  753.                          <span class="prnews_span">11.2.3</span>
  754.                        </p>
  755. </td>
  756. <td class="prngen5" colspan="1" rowspan="1">
  757. <p class="prnml4">
  758.                          <span class="prnews_span">Other Developmental Activities</span>
  759.                        </p>
  760. </td>
  761. </tr>
  762. <tr>
  763. <td class="prngen4" colspan="1" rowspan="1">
  764. <p class="prnml4">
  765.                          <span class="prnews_span">11.2.4</span>
  766.                        </p>
  767. </td>
  768. <td class="prngen5" colspan="1" rowspan="1">
  769. <p class="prnml4">
  770.                          <span class="prnews_span">Clinical Development</span>
  771.                        </p>
  772. </td>
  773. </tr>
  774. <tr>
  775. <td class="prngen4" colspan="1" rowspan="1">
  776. <p class="prnml4">
  777.                          <span class="prnews_span">11.2.4.1</span>
  778.                        </p>
  779. </td>
  780. <td class="prngen5" colspan="1" rowspan="1">
  781. <p class="prnml4">
  782.                          <span class="prnews_span">Clinical Trials Information</span>
  783.                        </p>
  784. </td>
  785. </tr>
  786. <tr>
  787. <td class="prngen4" colspan="1" rowspan="1">
  788. <p class="prnml4">
  789.                          <span class="prnews_span">11.2.5</span>
  790.                        </p>
  791. </td>
  792. <td class="prngen5" colspan="1" rowspan="1">
  793. <p class="prnml4">
  794.                          <span class="prnews_span">Safety and Efficacy</span>
  795.                        </p>
  796. </td>
  797. </tr>
  798. <tr>
  799. <td class="prngen4" colspan="1" rowspan="1">
  800. <p class="prnml4">
  801.                          <span class="prnews_span">11.3</span>
  802.                        </p>
  803. </td>
  804. <td class="prngen5" colspan="1" rowspan="1">
  805. <p class="prnml4">
  806.                          <span class="prnews_span">GRASTEK: ALK-Abello</span>
  807.                        </p>
  808. </td>
  809. </tr>
  810. <tr>
  811. <td class="prngen4" colspan="1" rowspan="1">
  812. <p class="prnml4">
  813.                          <span class="prnews_span">11.4</span>
  814.                        </p>
  815. </td>
  816. <td class="prngen5" colspan="1" rowspan="1">
  817. <p class="prnml4">
  818.                          <span class="prnews_span">RAGWITEK: Merck and ALK-Abello</span>
  819.                        </p>
  820. </td>
  821. </tr>
  822. <tr>
  823. <td class="prngen4" colspan="2" rowspan="1">
  824. <p class="prnml4">
  825.                          <span class="prnews_span">List to be continued in report….</span>
  826.                        </p>
  827. </td>
  828. </tr>
  829. <tr>
  830. <td class="prngen4" colspan="1" rowspan="1">
  831. <p class="prnml4">
  832.                          <span class="prnews_span">12</span>
  833.                        </p>
  834. </td>
  835. <td class="prngen5" colspan="1" rowspan="1">
  836. <p class="prnml4">
  837.                          <span class="prnews_span">Emerging Drugs for Allergic Rhino-Conjunctivitis</span>
  838.                        </p>
  839. </td>
  840. </tr>
  841. <tr>
  842. <td class="prngen4" colspan="1" rowspan="1">
  843. <p class="prnml4">
  844.                          <span class="prnews_span">12.1</span>
  845.                        </p>
  846. </td>
  847. <td class="prngen5" colspan="1" rowspan="1">
  848. <p class="prnml4">
  849.                          <span class="prnews_span">Key Competitors</span>
  850.                        </p>
  851. </td>
  852. </tr>
  853. <tr>
  854. <td class="prngen4" colspan="1" rowspan="1">
  855. <p class="prnml4">
  856.                          <span class="prnews_span">12.2</span>
  857.                        </p>
  858. </td>
  859. <td class="prngen5" colspan="1" rowspan="1">
  860. <p class="prnml4">
  861.                          <span class="prnews_span">MM09: Immunotek</span>
  862.                        </p>
  863. </td>
  864. </tr>
  865. <tr>
  866. <td class="prngen4" colspan="1" rowspan="1">
  867. <p class="prnml4">
  868.                          <span class="prnews_span">12.2.1</span>
  869.                        </p>
  870. </td>
  871. <td class="prngen5" colspan="1" rowspan="1">
  872. <p class="prnml4">
  873.                          <span class="prnews_span">Product Description</span>
  874.                        </p>
  875. </td>
  876. </tr>
  877. <tr>
  878. <td class="prngen4" colspan="1" rowspan="1">
  879. <p class="prnml4">
  880.                          <span class="prnews_span">12.2.2</span>
  881.                        </p>
  882. </td>
  883. <td class="prngen5" colspan="1" rowspan="1">
  884. <p class="prnml4">
  885.                          <span class="prnews_span">Other Developmental Activities</span>
  886.                        </p>
  887. </td>
  888. </tr>
  889. <tr>
  890. <td class="prngen4" colspan="1" rowspan="1">
  891. <p class="prnml4">
  892.                          <span class="prnews_span">12.2.3</span>
  893.                        </p>
  894. </td>
  895. <td class="prngen5" colspan="1" rowspan="1">
  896. <p class="prnml4">
  897.                          <span class="prnews_span">Clinical Development</span>
  898.                        </p>
  899. </td>
  900. </tr>
  901. <tr>
  902. <td class="prngen4" colspan="1" rowspan="1">
  903. <p class="prnml4">
  904.                          <span class="prnews_span">12.2.3.1</span>
  905.                        </p>
  906. </td>
  907. <td class="prngen5" colspan="1" rowspan="1">
  908. <p class="prnml4">
  909.                          <span class="prnews_span">Clinical Trial Information</span>
  910.                        </p>
  911. </td>
  912. </tr>
  913. <tr>
  914. <td class="prngen4" colspan="1" rowspan="1">
  915. <p class="prnml4">
  916.                          <span class="prnews_span">12.2.4</span>
  917.                        </p>
  918. </td>
  919. <td class="prngen5" colspan="1" rowspan="1">
  920. <p class="prnml4">
  921.                          <span class="prnews_span">Safety and Efficacy</span>
  922.                        </p>
  923. </td>
  924. </tr>
  925. <tr>
  926. <td class="prngen4" colspan="1" rowspan="1">
  927. <p class="prnml4">
  928.                          <span class="prnews_span">12.2.5</span>
  929.                        </p>
  930. </td>
  931. <td class="prngen5" colspan="1" rowspan="1">
  932. <p class="prnml4">
  933.                          <span class="prnews_span">Analyst Views</span>
  934.                        </p>
  935. </td>
  936. </tr>
  937. <tr>
  938. <td class="prngen4" colspan="2" rowspan="1">
  939. <p class="prnml4">
  940.                          <span class="prnews_span">List to be continued in report….</span>
  941.                        </p>
  942. </td>
  943. </tr>
  944. <tr>
  945. <td class="prngen4" colspan="1" rowspan="1">
  946. <p class="prnml4">
  947.                          <span class="prnews_span">13</span>
  948.                        </p>
  949. </td>
  950. <td class="prngen5" colspan="1" rowspan="1">
  951. <p class="prnml4">
  952.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market: 7MM Analysis </span>
  953.                        </p>
  954. </td>
  955. </tr>
  956. <tr>
  957. <td class="prngen4" colspan="1" rowspan="1">
  958. <p class="prnml4">
  959.                          <span class="prnews_span">13.1</span>
  960.                        </p>
  961. </td>
  962. <td class="prngen5" colspan="1" rowspan="1">
  963. <p class="prnml4">
  964.                          <span class="prnews_span">Key Findings</span>
  965.                        </p>
  966. </td>
  967. </tr>
  968. <tr>
  969. <td class="prngen4" colspan="1" rowspan="1">
  970. <p class="prnml4">
  971.                          <span class="prnews_span">13.2</span>
  972.                        </p>
  973. </td>
  974. <td class="prngen5" colspan="1" rowspan="1">
  975. <p class="prnml4">
  976.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market Outlook</span>
  977.                        </p>
  978. </td>
  979. </tr>
  980. <tr>
  981. <td class="prngen4" colspan="1" rowspan="1">
  982. <p class="prnml4">
  983.                          <span class="prnews_span">13.3</span>
  984.                        </p>
  985. </td>
  986. <td class="prngen5" colspan="1" rowspan="1">
  987. <p class="prnml4">
  988.                          <span class="prnews_span">Conjoint Analysis</span>
  989.                        </p>
  990. </td>
  991. </tr>
  992. <tr>
  993. <td class="prngen4" colspan="1" rowspan="1">
  994. <p class="prnml4">
  995.                          <span class="prnews_span">13.4</span>
  996.                        </p>
  997. </td>
  998. <td class="prngen5" colspan="1" rowspan="1">
  999. <p class="prnml4">
  1000.                          <span class="prnews_span">Key Allergic Rhino-Conjunctivitis Market Forecast Assumptions</span>
  1001.                        </p>
  1002. </td>
  1003. </tr>
  1004. <tr>
  1005. <td class="prngen4" colspan="1" rowspan="1">
  1006. <p class="prnml4">
  1007.                          <span class="prnews_span">13.5</span>
  1008.                        </p>
  1009. </td>
  1010. <td class="prngen5" colspan="1" rowspan="1">
  1011. <p class="prnml4">
  1012.                          <span class="prnews_span">Total Market Size of Allergic Rhino-Conjunctivitis in the 7MM</span>
  1013.                        </p>
  1014. </td>
  1015. </tr>
  1016. <tr>
  1017. <td class="prngen4" colspan="1" rowspan="1">
  1018. <p class="prnml4">
  1019.                          <span class="prnews_span">13.6</span>
  1020.                        </p>
  1021. </td>
  1022. <td class="prngen5" colspan="1" rowspan="1">
  1023. <p class="prnml4">
  1024.                          <span class="prnews_span">The United States Allergic Rhino-Conjunctivitis Market Size</span>
  1025.                        </p>
  1026. </td>
  1027. </tr>
  1028. <tr>
  1029. <td class="prngen4" colspan="1" rowspan="1">
  1030. <p class="prnml4">
  1031.                          <span class="prnews_span">13.6.1</span>
  1032.                        </p>
  1033. </td>
  1034. <td class="prngen5" colspan="1" rowspan="1">
  1035. <p class="prnml4">
  1036.                          <span class="prnews_span">Total Market Size Of Allergic Rhino-Conjunctivitis in the United States</span>
  1037.                        </p>
  1038. </td>
  1039. </tr>
  1040. <tr>
  1041. <td class="prngen4" colspan="1" rowspan="1">
  1042. <p class="prnml4">
  1043.                          <span class="prnews_span">13.6.2</span>
  1044.                        </p>
  1045. </td>
  1046. <td class="prngen5" colspan="1" rowspan="1">
  1047. <p class="prnml4">
  1048.                          <span class="prnews_span">Market Size of Allergic Rhino-Conjunctivitis by Therapies in the United States</span>
  1049.                        </p>
  1050. </td>
  1051. </tr>
  1052. <tr>
  1053. <td class="prngen4" colspan="1" rowspan="1">
  1054. <p class="prnml4">
  1055.                          <span class="prnews_span">13.7</span>
  1056.                        </p>
  1057. </td>
  1058. <td class="prngen5" colspan="1" rowspan="1">
  1059. <p class="prnml4">
  1060.                          <span class="prnews_span">EU4 and the UK Allergic Rhino-Conjunctivitis Market Size</span>
  1061.                        </p>
  1062. </td>
  1063. </tr>
  1064. <tr>
  1065. <td class="prngen4" colspan="1" rowspan="1">
  1066. <p class="prnml4">
  1067.                          <span class="prnews_span">13.8</span>
  1068.                        </p>
  1069. </td>
  1070. <td class="prngen5" colspan="1" rowspan="1">
  1071. <p class="prnml4">
  1072.                          <span class="prnews_span">Japan Allergic Rhino-Conjunctivitis Market Size</span>
  1073.                        </p>
  1074. </td>
  1075. </tr>
  1076. <tr>
  1077. <td class="prngen4" colspan="1" rowspan="1">
  1078. <p class="prnml4">
  1079.                          <span class="prnews_span">14</span>
  1080.                        </p>
  1081. </td>
  1082. <td class="prngen5" colspan="1" rowspan="1">
  1083. <p class="prnml4">
  1084.                          <span class="prnews_span">Unmet Needs Related to Allergic Rhino-Conjunctivitis</span>
  1085.                        </p>
  1086. </td>
  1087. </tr>
  1088. <tr>
  1089. <td class="prngen4" colspan="1" rowspan="1">
  1090. <p class="prnml4">
  1091.                          <span class="prnews_span">15</span>
  1092.                        </p>
  1093. </td>
  1094. <td class="prngen5" colspan="1" rowspan="1">
  1095. <p class="prnml4">
  1096.                          <span class="prnews_span">SWOT Analysis Related to Allergic Rhino-Conjunctivitis</span>
  1097.                        </p>
  1098. </td>
  1099. </tr>
  1100. <tr>
  1101. <td class="prngen4" colspan="1" rowspan="1">
  1102. <p class="prnml4">
  1103.                          <span class="prnews_span">16</span>
  1104.                        </p>
  1105. </td>
  1106. <td class="prngen5" colspan="1" rowspan="1">
  1107. <p class="prnml4">
  1108.                          <span class="prnews_span">KOL Views Related to Allergic Rhino-Conjunctivitis</span>
  1109.                        </p>
  1110. </td>
  1111. </tr>
  1112. <tr>
  1113. <td class="prngen4" colspan="1" rowspan="1">
  1114. <p class="prnml4">
  1115.                          <span class="prnews_span">17</span>
  1116.                        </p>
  1117. </td>
  1118. <td class="prngen5" colspan="1" rowspan="1">
  1119. <p class="prnml4">
  1120.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market Access and Reimbursement</span>
  1121.                        </p>
  1122. </td>
  1123. </tr>
  1124. <tr>
  1125. <td class="prngen4" colspan="1" rowspan="1">
  1126. <p class="prnml4">
  1127.                          <span class="prnews_span">17.1</span>
  1128.                        </p>
  1129. </td>
  1130. <td class="prngen5" colspan="1" rowspan="1">
  1131. <p class="prnml4">
  1132.                          <span class="prnews_span">The United States</span>
  1133.                        </p>
  1134. </td>
  1135. </tr>
  1136. <tr>
  1137. <td class="prngen4" colspan="1" rowspan="1">
  1138. <p class="prnml4">
  1139.                          <span class="prnews_span">17.2</span>
  1140.                        </p>
  1141. </td>
  1142. <td class="prngen5" colspan="1" rowspan="1">
  1143. <p class="prnml4">
  1144.                          <span class="prnews_span">EU4 and the UK</span>
  1145.                        </p>
  1146. </td>
  1147. </tr>
  1148. <tr>
  1149. <td class="prngen4" colspan="1" rowspan="1">
  1150. <p class="prnml4">
  1151.                          <span class="prnews_span">17.3</span>
  1152.                        </p>
  1153. </td>
  1154. <td class="prngen5" colspan="1" rowspan="1">
  1155. <p class="prnml4">
  1156.                          <span class="prnews_span">Japan</span>
  1157.                        </p>
  1158. </td>
  1159. </tr>
  1160. <tr>
  1161. <td class="prngen4" colspan="1" rowspan="1">
  1162. <p class="prnml4">
  1163.                          <span class="prnews_span">17.4</span>
  1164.                        </p>
  1165. </td>
  1166. <td class="prngen5" colspan="1" rowspan="1">
  1167. <p class="prnml4">
  1168.                          <span class="prnews_span">Market Access and Reimbursement of Allergic Rhino-Conjunctivitis</span>
  1169.                        </p>
  1170. </td>
  1171. </tr>
  1172. <tr>
  1173. <td class="prngen4" colspan="1" rowspan="1">
  1174. <p class="prnml4">
  1175.                          <span class="prnews_span">18</span>
  1176.                        </p>
  1177. </td>
  1178. <td class="prngen5" colspan="1" rowspan="1">
  1179. <p class="prnml4">
  1180.                          <span class="prnews_span">Bibliography</span>
  1181.                        </p>
  1182. </td>
  1183. </tr>
  1184. <tr>
  1185. <td class="prngen4" colspan="1" rowspan="1">
  1186. <p class="prnml4">
  1187.                          <span class="prnews_span">19</span>
  1188.                        </p>
  1189. </td>
  1190. <td class="prngen5" colspan="1" rowspan="1">
  1191. <p class="prnml4">
  1192.                          <span class="prnews_span">Allergic Rhino-Conjunctivitis Market Report Methodology</span>
  1193.                        </p>
  1194. </td>
  1195. </tr>
  1196. </table></div>
  1197. <p>
  1198.                  <b>Related Reports</b>
  1199.                </p>
  1200. <p>
  1201.                  <b><br />
  1202.                    <u><br />
  1203.                      <a href="https://www.delveinsight.com/report-store/allergic-rhino-conjunctivitis-pipeline-insight?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Allergic Rhino-Conjunctivitis Clinical Trial Analysis </a><br />
  1204.                    </u><br />
  1205.                  </b>
  1206.                </p>
  1207. <p>
  1208.                  <b>Allergic Rhino-Conjunctivitis Pipeline Insight – 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key allergic rhino-conjunctivitis companies, including <b>Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, </b>among others.</p>
  1209. <p>
  1210.                  <b><br />
  1211.                    <u><br />
  1212.                      <a href="https://www.delveinsight.com/report-store/allergic-conjunctivitis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Allergic Conjunctivitis Market</a><br />
  1213.                    </u><br />
  1214.                  </b>
  1215.                </p>
  1216. <p>
  1217.                  <b>Allergic Conjunctivitis Market Insights, Epidemiology, and Market Forecast – 2034 </b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key allergic conjunctivitis companies, including <b>Ocular Therapeutix, Santen Pharmaceutical, Aldeyra Therapeutics,</b> among others.</p>
  1218. <p>
  1219.                  <b><br />
  1220.                    <u><br />
  1221.                      <a href="https://www.delveinsight.com/report-store/allergic-conjunctivitis-pipeline-insight?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Allergic Conjunctivitis Clinical Trial Analysis</a><br />
  1222.                    </u><br />
  1223.                  </b>
  1224.                </p>
  1225. <p>
  1226.                  <b>Allergic Conjunctivitis Pipeline Insight – 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key allergic conjunctivitis companies, including<b> Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, </b>among others.</p>
  1227. <p>
  1228.                  <b><br />
  1229.                    <u><br />
  1230.                      <a href="https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" target="_blank" rel="nofollow">Hay Fever Conjunctivitis Market</a><br />
  1231.                    </u><br />
  1232.                  </b>
  1233.                </p>
  1234. <p>
  1235.                  <b>Hay Fever Conjunctivitis Market Insights, Epidemiology, and Market Forecast – 2034 </b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hay fever conjunctivitis companies, including <b>Novartis, Alcon Research, Bausch &amp; Lomb Incorporated, Aldeyra Therapeutics Inc, Vistakon Pharmaceuticals,</b> among others.</p>
  1236. <p>
  1237.                  <b>About DelveInsight</b>
  1238.                </p>
  1239. <p>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve<b>.</b></p>
  1240. <p>
  1241.                  <b>Contact Us :<br /></br></b>Shruti Thakur  <br /></br><a href="mailto:info@delveinsight.com" target="_blank" rel="nofollow">info@delveinsight.com</a><br /></br>+14699457679<br /></br><a href="https://www.delveinsight.com/" target="_blank" rel="nofollow">www.delveinsight.com</a> </p>
  1242. <p>Logo: <a href="https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg</a></p>
  1243. <p> </p>
  1244. <p id="PURL">
  1245.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN95991&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/allergic-rhino-conjunctivitis-market-poised-for-significant-growth-in-the-coming-10-years-amid-increasing-therapeutic-advancements--delveinsight-302581673.html" target="_blank">https://www.prnewswire.co.uk/news-releases/allergic-rhino-conjunctivitis-market-poised-for-significant-growth-in-the-coming-10-years-amid-increasing-therapeutic-advancements&#8211;delveinsight-302581673.html</a></p>
  1246. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN95991&amp;Transmission_Id=202510131731PR_NEWS_EURO_ND__EN95991&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  1247. ]]></content:encoded>
  1251. </item>
  1252. <item>
  1253. <title>FROM FRYING OIL TO COUPLING RELAYS: SIEMENS AND ENVALIOR COLLABORATE ON MORE SUSTAINABLE ELECTRICAL PRODUCTS</title>
  1254. <link>https://thenewsthisweek.co.uk/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products-27229/</link>
  1256. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  1257. <pubDate>Mon, 13 Oct 2025 20:30:00 +0000</pubDate>
  1258. <category><![CDATA[Brand Post]]></category>
  1259. <guid isPermaLink="false">https://thenewsthisweek.co.uk/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products-27229/</guid>
  1260.  
  1261. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="108" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="FROM FRYING OIL TO COUPLING RELAYS: SIEMENS AND ENVALIOR COLLABORATE ON MORE SUSTAINABLE ELECTRICAL PRODUCTS" decoding="async" loading="lazy" srcset="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products.jpg 144w, https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products-86x64.jpg 86w" sizes="auto, (max-width: 144px) 100vw, 144px" /></div>Siemens launches new SIRIUS 3RQ4 coupling relay with three versatile variants for a wide range of industrial requirements Ideal for use in combination with Siemens controllers Bio-based, halogen-free, flame-retardant Akulon® K225-KS B-MB plastic from Envalior offers high heat and excellent chemical resistance DÜSSELDORF, Germany, Oct. 13, 2025 /PRNewswire/ &#8212; Siemens Smart Infrastructure has launched a new [&#8230;]]]></description>
  1262. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="108" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="FROM FRYING OIL TO COUPLING RELAYS: SIEMENS AND ENVALIOR COLLABORATE ON MORE SUSTAINABLE ELECTRICAL PRODUCTS" decoding="async" loading="lazy" srcset="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products.jpg 144w, https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products-86x64.jpg 86w" sizes="auto, (max-width: 144px) 100vw, 144px" /></div><ul type="disc">
  1263. <li>
  1264.                    <b>Siemens launches new SIRIUS 3RQ4 coupling relay with three versatile variants for a wide range of industrial requirements</b>
  1265.                  </li>
  1266. <li>
  1267.                    <b>Ideal for use in combination with Siemens controllers </b>
  1268.                  </li>
  1269. <li>
  1270.                    <b>Bio-based, halogen-free, flame-retardant Akulon<sup>®</sup> K225-KS B-MB plastic from Envalior offers high heat and excellent chemical resistance</b>
  1271.                  </li>
  1272. </ul>
  1273. <p>
  1274.                  <span class="legendSpanClass">DÜSSELDORF, Germany</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; Siemens Smart Infrastructure has launched a new series of coupling relays, with housing made from plastic that consists of 70 percent bio-based material &#8211; derived from biomass waste. The Akulon® K225-KS B-MB plastic was developed by Envalior, a world leader in a wide range of industries by designing and developing high-quality sustainable solutions, in collaboration with Siemens to ensure all the desired properties are met. The plastic&#8217;s raw material comes from used cooking oil (UCO), left over after frying in the food industry, restaurants, snack bars and households. As UCO is no longer suitable for human or animal consumption, it does not compete with food or animal feed production. While UCO is mainly used for biodiesel, Envalior uses it for the production of engineering plastics based on a mass balance concept, avoiding incineration. Envalior is a global supplier of high-performance engineering materials.</p>
  1275. <div id="prni_dvprnejpg383fleft" dir="ltr" style="width: 100%; text-align: left;">
  1276.                  <img decoding="async" id="prnejpg383fleft" title="The new SIRIUS 3RQ4 coupling relay comes in three versatile variants for a wide range of industrial requirements. Photo: Siemens" src="https://mma.prnewswire.com/media/2794922/Envalior_BV___SIRIUS_3RQ4_coupling_relay.jpg" alt="The new SIRIUS 3RQ4 coupling relay comes in three versatile variants for a wide range of industrial requirements. Photo: Siemens" align="middle"></img>
  1277.                </div>
  1278. <p>&#8220;Collaborating with Envalior to create this bio-based plastic is an important step towards advancing the use of more sustainable materials in our electrical products. We are pleased to work with Envalior as another strong partner on our journey towards a more environmentally friendly portfolio,&#8221; says Andreas Matthé, CEO of Electrical Products at Siemens Smart Infrastructure.</p>
  1279. <p>The new SIRIUS 3RQ4 coupling relay comes in three versatile variants for a wide range of industrial requirements. </p>
  1280. <p>The first variant with integral relay output is specially designed for harsh environmental conditions, as well as for areas with specific safety requirements. These relays have safety-ready characteristic values (B10d values) and are also approved for use in potentially explosive atmospheres (ATEX-certified). This variant is optionally available with gold-plated contact elements for switching very low currents, or with printed circuit boards with a protective coating, which are suited for railway applications. </p>
  1281. <p>As a second variant, plug-in coupling relays are available for applications that require quick relay replacement during operation. They are also available as an option with gold-plated contacts. </p>
  1282. <p>For applications requiring very fast, soundless and frequent switching, Siemens offers a third variant with semiconductor output. As it has a virtually infinite service life, it is used where replacing conventional relays can be expensive and time-consuming. Siemens has been able to increase the switching capacity of these semiconductor variants to up to 6A, enabling them to match the performance of conventional elementary relays. </p>
  1283. <p>The SIRIUS 3RQ4 coupling relays are designed for more sustainability throughout their entire lifecycle, from development to the end of service life and meet the strict criteria of the Siemens EcoTech label. This includes 33 percent lower energy losses in the semiconductor variant compared to previous versions as well as eliminating problematic materials such as halogens or PFAS.</p>
  1284. <p>In addition, the product can be easily dismantled and recycled at the end of its life. Envalior&#8217;s Akulon® K225-KS B-MB, a bio-based, halogen-free, flame-retardant polyamide 6 grade plastic for injection molding, is the ideal choice for these coupling relays. This more sustainable material is characterized by a significantly improved environmental profile, high heat resistance, and excellent chemical resistance and is used in many electrical engineering and power distribution applications.</p>
  1285. <p>&#8220;At Envalior, we are proud to have partnered with Siemens in the development of the SIRIUS 3RQ4 coupling relay series. A key success factor in this project was achieving excellent flow behavior in thin-wall designs and a UL94 V-0 rating at just 0.4 mm thickness, while simultaneously achieving an outstanding green share from bio-waste sources but at prime quality,&#8221; says Dr. Marc Rudolf, Global Key Account Manager, Envalior.</p>
  1286. <p>The new SIRIUS 3RQ4 coupling relays have a space-saving slim-line design for optimized use in control cabinets. They have been designed and intensively tested for use in combination with Siemens controllers. Their fully automated production at the Siemens plant in Amberg shortens the supply chain in the German and European markets. The coupling relays are shipped in more sustainable cardboard boxes in standard multi-piece packaging. The operating instructions and all relevant information can be accessed electronically from an ID link on the device. </p>
  1287. <p>In addition to the manufacture of bio-based products, Envalior also focuses on renewable energies. In 2024, Envalior covered over 50 percent of its global electricity needs with renewable energies. By 2030, Envalior aims to reduce emissions by another 35 percent. This will be achieved through a variety of measures, including expanding renewable energies to 100 percent by 2030, implementing local emission reduction initiatives, and switching to climate-friendly heat sources. Envalior invests in renewable energies close to its production sites around the world. </p>
  1288. <p>Visit Envalior for more information at K 2025 (Hall 6, Stand B11, October 8-15, 2025, Messe Düsseldorf, Germany) or at <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531528-1&amp;h=3737081181&amp;u=https%3A%2F%2Fwww.envalior.com%2Fen-us%2Fproducts&amp;a=https%3A%2F%2Fwww.envalior.com%2Fen-us%2Fproducts" target="_blank" rel="nofollow">https://www.envalior.com/en-us/products</a>.</p>
  1289. <p>For more information on Siemens Smart Infrastructure, please see <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531528-1&amp;h=1782850698&amp;u=https%3A%2F%2Fwww.siemens.com%2Fglobal%2Fen%2Fcompany%2Fabout%2Fbusinesses%2Fsmart-infrastructure.html&amp;a=Siemens+Smart+Infrastructure" target="_blank" rel="nofollow">Siemens Smart Infrastructure</a>.</p>
  1290. <p>
  1291.                  <b><br />
  1292.                    <i>About Envalior<br /></br></i><br />
  1293.                  </b><br />
  1294.                  <i>Envalior is a global leader in Engineering Materials with over 4,000 employees worldwide. It was established in 2023 through the merger of Lanxess Performance Materials and DSM Engineering Materials. With a long track record of customer-driven innovation, Envalior specializes in developing Sustainable and High-Performance Engineering Materials, including PA6, PA66, PBT, PA46, PPS, TPC, PET, PA4T, PA410, and Thermoplastic Composites. Focus markets include Mobility, Electronics &amp; Electrical, and Consumer Goods. For more information, visit </i><br />
  1295.                  <i><br />
  1296.                    <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531528-1&amp;h=1390701658&amp;u=https%3A%2F%2Fwww.envalior.com%2Fen-us%2Fhome&amp;a=www.envalior.com" target="_blank" rel="nofollow">www.envalior.com</a><br />
  1297.                  </i><br />
  1298.                  <i>.</i>
  1299.                </p>
  1300. <p>
  1301.                  <b><br />
  1302.                    <i>About Siemens<br /></br></i><br />
  1303.                  </b><br />
  1304.                  <i>Siemens Smart Infrastructure (SI) is shaping the market for intelligent, adaptive infrastructure for today and the future. It addresses the pressing challenges of urbanization and climate change by connecting energy systems, buildings, and industries. SI provides customers with a comprehensive end-to-end portfolio from a single source – with products, systems, solutions, and services from the point of power generation all the way to consumption. With an increasingly digitalized ecosystem, it helps customers thrive and communities progress while contributing toward protecting the planet. To protect this journey, we foster holistic cybersecurity to ensure secure and reliable operations. Siemens Smart Infrastructure has its global headquarters in Zug, Switzerland. As of September 30, 2024, the business had around 78,500 employees worldwide.</i>
  1305.                </p>
  1306. <p>
  1307.                  <i>Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company&#8217;s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at </i><br />
  1308.                  <i><br />
  1309.                    <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531528-1&amp;h=3941389002&amp;u=https%3A%2F%2Fwww.siemens.com%2F&amp;a=www.siemens.com" target="_blank" rel="nofollow">www.siemens.com</a><br />
  1310.                  </i><br />
  1311.                  <i>.</i>
  1312.                </p>
  1313. <div id="prni_dvprnejpg7d90left" dir="ltr" style="width: 100%; text-align: left;">
  1314.                  <img decoding="async" id="prnejpg7d90left" title="Process steps – from more sustainable raw material to finished coupling relays. Infographic: Siemens" src="https://mma.prnewswire.com/media/2794923/Envalior_BV___Graphic_SIRIUS_Process_overview.jpg" alt="Process steps – from more sustainable raw material to finished coupling relays. Infographic: Siemens" align="middle"></img>
  1315.                </div>
  1316. <p> </p>
  1317. <div id="prni_dvprnejpg91f6left" dir="ltr" style="width: 100%; text-align: left;">
  1318.                  <img decoding="async" id="prnejpg91f6left" title=" " src="https://mma.prnewswire.com/media/2532459/Logo_Logo.jpg" alt=" " align="middle"></img>
  1319.                </div>
  1320. <p>Photo &#8211; <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531528-1&amp;h=2643496770&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2794922%2FEnvalior_BV___SIRIUS_3RQ4_coupling_relay.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2794922%2FEnvalior_BV___SIRIUS_3RQ4_coupling_relay.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2794922/Envalior_BV___SIRIUS_3RQ4_coupling_relay.jpg</a>  <br /></br>Photo &#8211; <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531528-1&amp;h=3630914577&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2794923%2FEnvalior_BV___Graphic_SIRIUS_Process_overview.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2794923%2FEnvalior_BV___Graphic_SIRIUS_Process_overview.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2794923/Envalior_BV___Graphic_SIRIUS_Process_overview.jpg</a> <br /></br>Logo &#8211;<span> </span><a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531528-1&amp;h=3515673883&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2532459%2FLogo_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2532459%2FLogo_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2532459/Logo_Logo.jpg</a> </p>
  1321. <p id="PURL">
  1322.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96589&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products-302582458.html" target="_blank">https://www.prnewswire.co.uk/news-releases/from-frying-oil-to-coupling-relays-siemens-and-envalior-collaborate-on-more-sustainable-electrical-products-302582458.html</a></p>
  1323. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96589&amp;Transmission_Id=202510131630PR_NEWS_EURO_ND__EN96589&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  1324. ]]></content:encoded>
  1328. </item>
  1329. <item>
  1330. <title>Gemstones Market to Reach USD 101.01 Billion by 2032, Growing At An 6.3% CAGR &#8211; Credence Research</title>
  1331. <link>https://thenewsthisweek.co.uk/gemstones-market-to-reach-usd-101-01-billion-by-2032-growing-at-an-6-3-cagr-credence-research-27231/</link>
  1333. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  1334. <pubDate>Mon, 13 Oct 2025 19:49:00 +0000</pubDate>
  1335. <category><![CDATA[Brand Post]]></category>
  1336. <guid isPermaLink="false">https://thenewsthisweek.co.uk/gemstones-market-to-reach-usd-101-01-billion-by-2032-growing-at-an-6-3-cagr-credence-research-27231/</guid>
  1337.  
  1338. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="115" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/gemstones-market-to-reach-usd-101-01-billion-by-2032-growing-at-an-6-3-cagr-credence-research.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Gemstones Market to Reach USD 101.01 Billion by 2032, Growing At An 6.3% CAGR - Credence Research" decoding="async" loading="lazy" /></div>PUNE, India, Oct. 13, 2025 /PRNewswire/ &#8212; The global gemstones market continues to demonstrate robust growth momentum, driven by evolving consumer preferences, technological advancements, and increasing affluence in emerging economies. According to new market intelligence, the gemstones market size was valued at USD 58,291.02 million in 2023 and is anticipated to reach USD 101.01billion by 2032, [&#8230;]]]></description>
  1339. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="115" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/gemstones-market-to-reach-usd-101-01-billion-by-2032-growing-at-an-6-3-cagr-credence-research.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Gemstones Market to Reach USD 101.01 Billion by 2032, Growing At An 6.3% CAGR - Credence Research" decoding="async" loading="lazy" /></div><p>
  1340.                  <span class="legendSpanClass">PUNE, India</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; <i>The global gemstones market continues to demonstrate robust growth momentum, driven by evolving consumer preferences, technological advancements, and increasing affluence in emerging economies. According to new market intelligence, the gemstones market size was valued at USD 58,291.02 million in 2023 and is anticipated to reach USD 101.01billion by 2032, expanding at a compound annual growth rate (CAGR) of 6.30% during the forecast period.</i></p>
  1341. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
  1342. <p>
  1343.                    <a href="https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.html" target="_blank" rel="nofollow"><br />
  1344.                      <img decoding="async" src="https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg" title="Credence Research Logo (PRNewsfoto/Credence Research Inc.)" alt="Credence Research Logo (PRNewsfoto/Credence Research Inc.)"></img><br />
  1345.                    </a>
  1346.                  </p>
  1347. </p></div>
  1348. <p>
  1349.                  <b>Market Overview</b>
  1350.                </p>
  1351. <p>The <a href="https://www.credenceresearch.com/report/gemstones-market" target="_blank" rel="nofollow">gemstones market</a> encompasses a diverse range of precious and semi-precious stones, including diamonds, rubies, sapphires, emeralds, and other colored gemstones used primarily in jewelry, investment, and industrial applications. The industry has witnessed transformative changes in recent years, with sustainability concerns, transparency initiatives, and the emergence of lab-grown alternatives reshaping traditional market dynamics. The market&#8217;s expansion from USD 58,291.02 million in 2023 to an anticipated USD 101,018.53 million by 2032 reflects a sustained CAGR of 6.30%, underscoring strong consumer confidence and growing demand across multiple segments and geographic regions.</p>
  1352. <p>North America currently holds the dominant position in the global gemstones market, capturing 36.59% of total revenue share in 2024, driven by high consumer purchasing power and preference for certified, ethically sourced gemstones. However, the Asia-Pacific region is emerging as the fastest-growing market, propelled by rapid urbanization, rising disposable incomes, and the cultural significance of gemstones in countries such as China, India, and Japan. The industry landscape features a mix of established mining giants like De Beers Group, PJSC ALROSA, and Rio Tinto Diamonds, alongside emerging synthetic gemstone producers and specialized retailers who are leveraging vertical integration and technological innovation to maintain competitive advantages.</p>
  1353. <p>
  1354.                  <b><br />
  1355.                    <i>Browse the report and understand how it can benefit your business strategy &#8211;</i><br />
  1356.                    <u><br />
  1357.                      <a href="https://www.credenceresearch.com/report/gemstones-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/gemstones-market</a><br />
  1358.                    </u><br />
  1359.                  </b>
  1360.                </p>
  1361. <p>
  1362.                  <b>Key Growth Determinants</b>
  1363.                </p>
  1364. <p>Rising Consumer Demand for Ethical and Sustainable Gemstones</p>
  1365. <p>Growing awareness of environmental and social issues has fundamentally transformed consumer purchasing behavior in the gemstones market, with buyers increasingly prioritizing transparency and ethical sourcing practices. This shift is particularly pronounced among millennial and Gen Z consumers who seek luxury products that align with their values regarding sustainability and social responsibility. Companies are responding by implementing rigorous traceability systems and obtaining certifications such as the Kimberley Process to verify ethical origins. Gemfields&#8217; expansion of ethical sourcing initiatives in March 2024 exemplifies this trend, as the company enhanced supply chain transparency to build consumer trust and differentiate its colored gemstones offering. Retailers and brands that can demonstrate authentic provenance through blockchain technology and third-party certification are gaining significant market share, particularly in developed markets where consumers are willing to pay premium prices for responsibly sourced gemstones.</p>
  1366. <p>
  1367.                  <b>Expansion of Lab-Grown and Synthetic Gemstone Segment</b>
  1368.                </p>
  1369. <p>The lab-grown gemstone segment has emerged as a transformative force in the industry, offering chemically identical alternatives to natural stones at significantly lower price points while eliminating environmental concerns associated with traditional mining. The global lab-grown diamond market was valued at USD 22.79 billion in 2023 and is projected to reach USD 74.45 billion by 2032, exhibiting a CAGR of 14.11%, substantially outpacing the natural gemstone segment. Technological advancements in Chemical Vapor Deposition (CVD) and High Pressure High Temperature (HPHT) manufacturing processes have enabled producers to create high-quality synthetic gemstones within weeks rather than the millennia required for natural formation. Major industry players including De Beers, Charles &amp; Colvard, and Swarovski Group have launched dedicated lab-grown collections, legitimizing the segment and accelerating consumer acceptance. This democratization of luxury is particularly appealing to younger consumers seeking affordable yet authentic gemstone jewelry for engagements, fashion, and personal expression.</p>
  1370. <p>
  1371.                  <b>Digital Transformation and E-Commerce Expansion</b>
  1372.                </p>
  1373. <p>The digital revolution has fundamentally altered the gemstone buying experience, providing consumers with unprecedented access to certified gemstones through online platforms that offer transparent pricing, detailed product information, and virtual try-on features. E-commerce platforms have eliminated traditional geographic barriers, enabling direct-to-consumer business models that reduce intermediary costs and improve price competitiveness. Social media and influencer marketing have become powerful drivers of consumer engagement, with brands leveraging Instagram, YouTube, and TikTok to showcase gemstone jewelry and educate consumers about quality, certification, and styling. The COVID-19 pandemic accelerated this digital transition, as temporary retail closures forced both established jewelers and gemstone dealers to develop robust online sales channels. Advanced technologies including augmented reality for virtual try-ons, AI-driven personalization, and blockchain-based authentication are enhancing consumer confidence and expanding the addressable market beyond traditional luxury jewelry retail environments.</p>
  1374. <p>
  1375.                  <b>Key Growth Barriers</b>
  1376.                </p>
  1377. <p>
  1378.                  <b>Supply Chain Complexity and Transparency Challenges</b>
  1379.                </p>
  1380. <p>The gemstones industry faces significant supply chain obstacles stemming from the fragmented nature of sourcing, particularly in the colored gemstone segment where approximately 80% of the USD 3.2 billion market originates from small-scale artisanal mining communities. Poor record-keeping practices, excessive intermediaries inflating prices, and hidden treatments that alter stone qualities create substantial transparency challenges throughout the value chain. Geopolitical instability in resource-rich regions including Africa and Russia further complicates material sourcing, with trade restrictions and sanctions impacting availability and causing cost increases. Transportation bottlenecks, port congestion, and natural disasters add additional layers of complexity and unpredictability to global supply networks. The absence of standardized certification protocols across different gemstone hubs such as Antwerp for diamonds and Bangkok for colored stones enables synthetic stones to infiltrate markets, undermining consumer confidence. Despite promising technological solutions like blockchain-based tracking systems, only 12% of colored gemstone traders have adopted such platforms due to technical barriers and implementation costs.</p>
  1381. <p>
  1382.                  <b>Price Volatility and Economic Sensitivity</b>
  1383.                </p>
  1384. <p>Gemstones, particularly high-value precious stones, function as luxury goods whose demand exhibits significant sensitivity to macroeconomic conditions and consumer confidence levels. Economic downturns, inflation, and currency fluctuations directly impact consumer discretionary spending on jewelry and investment-grade gemstones, creating revenue volatility for industry participants. The rapid growth of lab-grown alternatives has introduced substantial pricing pressure on natural gemstone segments, with synthetic diamonds selling for approximately 10% of equivalent natural stone prices, fundamentally altering value perceptions. This pricing disruption threatens traditional business models built around scarcity and provenance premiums associated with natural gemstones. Market fragmentation across different gemstone types, qualities, and origins creates inconsistent pricing structures that confuse consumers and complicate valuation processes. Investment-grade gemstones face additional challenges from competing asset classes including precious metals, cryptocurrency, and traditional financial instruments that offer greater liquidity and transparent pricing mechanisms.</p>
  1385. <p>
  1386.                  <b>Regulatory Compliance and Certification Costs</b>
  1387.                </p>
  1388. <p>The gemstones industry operates under increasingly stringent regulatory frameworks designed to prevent conflict financing, ensure ethical labor practices, and verify authenticity, creating significant compliance burdens particularly for smaller market participants. Certification by leading gemological institutes such as GIA and IGI, while enhancing consumer confidence, adds substantial costs that range from hundreds to thousands of dollars per stone depending on size and complexity. Disparate regulations across major gemstone markets including the United States, European Union, and Asia-Pacific create compliance complexity for international traders and manufacturers. The Kimberley Process, while establishing baseline standards for conflict-free diamonds, has faced criticism regarding implementation inconsistencies and limited applicability to colored gemstones. Emerging requirements for blockchain-based traceability and digital certificates require technological investments exceeding $500,000 for AI-driven sorting systems, limiting accessibility for small-scale miners and traders who lack capital resources. These regulatory and certification barriers create market concentration risks by favoring large, vertically integrated players with resources to navigate complex compliance landscapes..</p>
  1389. <p>
  1390.                  <b><br />
  1391.                    <i>Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today &#8211;</i><br />
  1392.                  </b><br />
  1393.                  <a href="https://www.credenceresearch.com/report/gemstones-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/gemstones-market</a>
  1394.                </p>
  1395. <p>
  1396.                  <b>Key Market Trends</b>
  1397.                </p>
  1398. <p>
  1399.                  <b>Blockchain Technology for Gemstone Authentication and Traceability</b>
  1400.                </p>
  1401. <p>Blockchain technology has emerged as a transformative solution for addressing long-standing transparency and authentication challenges in the gemstones supply chain, with major industry players implementing distributed ledger systems to track stones from mine to retail. De Beers&#8217; Tracr platform represents the most significant blockchain initiative, creating a tamper-proof digital registry that records individual diamonds&#8217; provenance, characteristics, and ownership transfers across the value chain. In a landmark development, Russian diamond producer Alrosa joined the Tracr platform, meaning the world&#8217;s two largest diamond producers, accounting for approximately 80% of rough diamonds by value, now collaborate on blockchain-based authentication.</p>
  1402. <p>The technology integrates sophisticated identification techniques including Sarine scans, gemological reports, and Kimberley Process certificates into immutable digital records that verify connections between physical stones and their digital twins. Everledger has pioneered blockchain applications for colored gemstones, enabling artisanal miners to independently document location, timing, and imagery at extraction points, connecting directly to international markets with enhanced provenance verification. Despite promising applications, blockchain adoption remains limited with only 12% of colored gemstone traders utilizing such systems due to technical complexity and implementation costs.</p>
  1403. <p>
  1404.                  <b>Customization and Personalization in Gemstone Jewelry</b>
  1405.                </p>
  1406. <p>Consumer demand for unique, personalized gemstone jewelry has accelerated significantly, driven by desires for self-expression and pieces with emotional significance rather than generic mass-market designs. This trend manifests through bespoke engagement rings featuring non-traditional colored gemstones, birthstone jewelry with family connections, and custom-designed pieces incorporating heirloom stones with contemporary settings. Advanced 3D printing and computer-aided design technologies have democratized custom jewelry creation, enabling smaller independent jewelers to offer personalization services previously available only through high-end luxury houses.</p>
  1407. <p>The rise of direct-to-consumer business models facilitated by e-commerce platforms allows consumers to participate actively in design processes, selecting specific gemstones and working with designers remotely throughout creation. Younger consumers, particularly millennials and Gen Z buyers, exhibit strong preferences for individuality over traditional luxury brand names, seeking gemstone jewelry that tells personal stories and reflects unique aesthetic sensibilities. Astrological and spiritual associations with specific gemstones have experienced renewed popularity, particularly in India where the market is growing at 11.4% CAGR driven by gemstones&#8217; cultural significance for ceremonies and auspicious occasions.</p>
  1408. <p>
  1409.                  <b>Growing Popularity of Colored Gemstones Beyond Traditional &#8220;Big Three&#8221;</b>
  1410.                </p>
  1411. <p>The colored gemstone market is experiencing diversification beyond the traditional &#8220;big three&#8221; of rubies, sapphires, and emeralds, with consumers seeking rare and distinctive stones including spinel, tanzanite, and tourmaline. Market data from the 2025 Tucson gem shows indicates focused buying activity concentrated on high-end rare goods, with particular demand for vibrant green and orange-red stones, Ethiopian opal, and phenomenal gems displaying optical effects. This trend reflects sophisticated consumer knowledge and appreciation for gemological properties beyond conventional precious stone categories.</p>
  1412. <p>Collectors and investors are increasingly targeting stones with unique characteristics, geographic origin stories, and scarcity profiles that offer differentiation and potential value appreciation. The shift benefits producing countries with rich colored gemstone deposits, including Zambia for emeralds, Mozambique for rubies, Madagascar for sapphires, and Colombia for emeralds, creating economic opportunities for mining communities. Retail demand in the United States remains particularly robust for rare and high-quality colored stones, with the market outlook for 2025 characterized as &#8220;sparkling&#8221; by industry analysts.</p>
  1413. <p>
  1414.                  <b>Key Opportunities</b>
  1415.                </p>
  1416. <p>
  1417.                  <b>Asia-Pacific Market Expansion and Rising Middle-Class Affluence</b>
  1418.                </p>
  1419. <p>The Asia-Pacific region presents the most significant growth opportunity for the gemstones market, with projections indicating it will achieve the fastest CAGR from 2025 to 2032 driven by increasing affluence, urbanization, and cultural affinity for gemstones. China led the region with the largest market share in 2024, propelled by a rising middle class, gift-giving culture, and growing interest in personalized luxury items including diamonds, jade, sapphires, and rubies. India&#8217;s gemstone market is expected to grow at an exceptional CAGR of 11.4% from 2025 to 2035, fueled by gemstones&#8217; cultural importance for astrological and spiritual purposes, along with rising disposable incomes and expanding organized retail infrastructure.</p>
  1420. <p>Government support for gemstone processing hubs and expansion of e-commerce platforms in countries including Thailand, Sri Lanka, and Vietnam is facilitating market penetration and creating direct connections between producers and consumers. Japan exhibits growing interest in high-quality rare stones for luxury gifting, with cultural emphasis on minimalism and quality driving demand for refined gemstone jewelry and birthstone-related purchases. The region&#8217;s demographic advantages including large populations, increasing urbanization rates, and expanding middle-class segments create sustained long-term demand drivers that transcend short-term economic cycles.</p>
  1421. <p>
  1422.                  <b>Investment-Grade Gemstones as Alternative Assets</b>
  1423.                </p>
  1424. <p>Gemstones are increasingly recognized as viable alternative investment assets, offering portfolio diversification, inflation hedging, and store-of-value characteristics particularly for rare, high-quality stones with authenticated provenance. Investment interest has intensified following market volatility in traditional asset classes, with colored gemstones experiencing robust growth from 2020 to 2024 despite pandemic disruptions and global economic uncertainties. High-net-worth individuals and family offices are allocating capital to investment-grade diamonds, Burmese rubies, Kashmir sapphires, and Colombian emeralds as portable, tangible wealth stores with historical price appreciation.</p>
  1425. <p>Gemfields&#8217; ruby auctions featuring exceptional Mozambique rubies measuring 61.50 carats uncut have attracted collectors and investors seeking premium gemstones for exclusive jewelry creations and long-term holdings. Certification by prestigious gemological institutes and blockchain-based authentication systems enhance investment confidence by providing verifiable documentation of quality, origin, and ownership history. The establishment of gemstone investment funds and fractional ownership platforms utilizing NFT technology creates accessibility for smaller investors while maintaining liquidity through secondary trading markets.</p>
  1426. <p>
  1427.                  <b>Technological Integration in Mining, Cutting, and Retail Operations</b>
  1428.                </p>
  1429. <p>Advanced technologies are creating operational efficiencies and value-creation opportunities across the gemstones value chain, from extraction through retail distribution. AI-driven sorting technologies improve yield quality and reduce waste in mining and processing operations, though capital requirements exceeding $500,000 currently limit adoption to larger enterprises.</p>
  1430. <p>Computer-aided design and precision cutting equipment enable optimization of finished gemstone dimensions, maximizing carat weight while achieving desired optical properties including brilliance and fire. Nanoparticle tagging technologies offer potential solutions for gemstone tracking at molecular levels, providing authentication that persists even when stones are recut or reset in new jewelry designs. Virtual try-on features utilizing augmented reality technology enhance online shopping experiences, addressing traditional barriers to e-commerce adoption in the jewelry sector where consumers prefer physical examination.</p>
  1431. <p>Data analytics and machine learning applications enable retailers to optimize inventory management, predict consumer preferences, and personalize marketing communications based on browsing behavior and purchase history. Integration of cryptocurrency payment systems and NFT-based ownership certificates creates new market segments and facilitates international transactions while reducing payment processing costs and settlement times.</p>
  1432. <p>
  1433.                  <b>Segmentation</b>
  1434.                </p>
  1435. <p>
  1436.                  <b>Based on Type:</b>
  1437.                </p>
  1438. <ul type="disc">
  1439. <li>Diamond</li>
  1440. <li>Sapphires</li>
  1441. <li> Rubies</li>
  1442. <li> Emeralds</li>
  1443. <li>Opals</li>
  1444. <li> Pearls</li>
  1445. <li>Amber</li>
  1446. <li>Aquamarine</li>
  1447. <li>Topaz</li>
  1448. <li>Garnets</li>
  1449. <li> Tanzanite</li>
  1450. <li>Tourmaline</li>
  1451. </ul>
  1452. <p>
  1453.                  <b>Based on</b> <b>Quality and Grading:</b></p>
  1454. <ul type="disc">
  1455. <li>Gemstone Quality</li>
  1456. <li> Certified Gemstones</li>
  1457. </ul>
  1458. <p>
  1459.                  <b>Based on</b> <b>Origin:</b></p>
  1460. <ul type="disc">
  1461. <li>Natural Gemstones</li>
  1462. <li> Synthetic Gemstones</li>
  1463. <li>Enhanced Gemstones</li>
  1464. </ul>
  1465. <p>
  1466.                  <b>Based on Applications:</b>
  1467.                </p>
  1468. <ul type="disc">
  1469. <li>Jewellery</li>
  1470. <li>Watches</li>
  1471. <li>Home Decor</li>
  1472. <li>Spiritual and Healing</li>
  1473. </ul>
  1474. <p>
  1475.                  <b> Based on Distribution Channel:</b>
  1476.                </p>
  1477. <ul type="disc">
  1478. <li> Jewellery Stores</li>
  1479. <li> Online Retailers</li>
  1480. <li>Auction Houses</li>
  1481. <li>Gemstone Shows and Fairs</li>
  1482. <li> Direct from Miners</li>
  1483. </ul>
  1484. <p>
  1485.                  <b> Based on Region:</b>
  1486.                </p>
  1487. <ul type="disc">
  1488. <li>North America</li>
  1489. <ul type="circle">
  1490. <li>United States</li>
  1491. <li>Canada</li>
  1492. </ul>
  1493. <li>Europe</li>
  1494. <ul type="circle">
  1495. <li>United Kingdom</li>
  1496. <li>Germany</li>
  1497. <li>France</li>
  1498. </ul>
  1499. <li>Asia-Pacific</li>
  1500. <ul type="circle">
  1501. <li>China</li>
  1502. <li>India</li>
  1503. <li>Japan</li>
  1504. </ul>
  1505. <li>Latin America</li>
  1506. <ul type="circle">
  1507. <li>Brazil</li>
  1508. <li>Mexico</li>
  1509. </ul>
  1510. <li>Middle East &amp; Africa</li>
  1511. <ul type="circle">
  1512. <li>South Africa</li>
  1513. <li>United Arab Emirates</li>
  1514. </ul>
  1515. </ul>
  1516. <p>
  1517.                  <b>Regional Analysis</b>
  1518.                </p>
  1519. <p>North America maintains market dominance with 36.59% revenue share in 2024, driven by strong demand for high-quality natural and precious stones in the luxury jewelry sector, particularly for engagement rings and investment purposes.</p>
  1520. <p>The United States captured the largest share within North America, supported by rising disposable incomes, customized jewelry preferences, and increasing interest in both colored gemstones and lab-grown alternatives among younger consumers prioritizing ethical sourcing. Europe demonstrates steady growth prospects, with the United Kingdom exhibiting robust expansion fueled by demand for ethical and traceable gemstones at a CAGR of 5.9%, while Germany&#8217;s market expands through high awareness of certification and preference for investment-grade stones.</p>
  1521. <p>The Asia-Pacific region represents the fastest-growing market globally, with China leading through rising middle-class affluence, gift-giving traditions, and demand for diamonds and jade, while government support for domestic manufacturing and e-commerce growth accelerates sectoral expansion. India&#8217;s exceptional 11.4% CAGR reflects gemstones&#8217; cultural significance for astrology and ceremonies, combined with urbanization and expanding retail infrastructure.</p>
  1522. <p>Japan contributes through demand for high-quality rare stones and culturally significant gems including jade and pearls within its tradition-rich consumer base. The Middle East and Africa serve dual roles as major gemstone suppliers and growing consumer markets, with Africa&#8217;s position as a prominent global gemstone source complemented by rising demand for customized jewelry in affluent Gulf nations. Latin America, particularly Brazil, exhibits growing market potential driven by both domestic consumption and positioning as a gemstone production hub serving global markets.</p>
  1523. <p>
  1524.                  <b>Credence Research&#8217;s Competitive Landscape Analysis</b>
  1525.                </p>
  1526. <p>Credence Research&#8217;s competitive landscape analysis reveals a dynamic market structure characterized by intense competition among established mining conglomerates, specialized gemstone producers, and emerging synthetic stone manufacturers.</p>
  1527. <p>Tier-1 players including De Beers Group, PJSC ALROSA, and Rio Tinto Diamonds collectively control 35-40% market share through extensive sourcing networks, vertical integration, and strong luxury brand partnerships. These industry leaders leverage robust distribution infrastructure, substantial brand equity, and access to high-quality certified gemstones including rare investment-grade stones that appeal to affluent consumers and institutional investors. Mid-tier players such as Gemfields Group, Petra Diamonds Limited, and Fura Gems Inc. compete through specialization in specific gemstone categories, ethical sourcing differentiation, and strategic designer collaborations that enhance brand visibility.</p>
  1528. <p>The competitive landscape is being disrupted by synthetic gemstone producers including Charles &amp; Colvard, Swarovski Group, and numerous Indian and Chinese manufacturers who offer cost-effective, sustainable alternatives that challenge traditional natural stone value propositions. Strategic partnerships exemplified by Charles &amp; Colvard&#8217;s October 2025 collaboration with Ethara Capital demonstrate industry consolidation trends and vertical integration efforts to control supply chains from production through retail distribution. Companies investing in blockchain-based traceability systems, sustainability certifications, and digital sales channels are positioned to capture growing market segments prioritizing transparency, ethical sourcing, and convenient online purchasing experiences.</p>
  1529. <p>
  1530.                  <b><br />
  1531.                    <i>Tailor the report to align with your specific business needs and gain targeted insights. Request Here &#8211; <a href="https://www.credenceresearch.com/report/gemstones-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/gemstones-market</a></i><br />
  1532.                  </b>
  1533.                </p>
  1534. <p>
  1535.                  <b>Key Player Analysis</b>
  1536.                </p>
  1537. <ul type="disc">
  1538. <li>Arctic Star Exploration Corp.</li>
  1539. <li>Diamcor Mining Inc</li>
  1540. <li>Swarovski Group</li>
  1541. <li>Stornoway Diamond Corporation</li>
  1542. <li>Petra Diamonds Limited</li>
  1543. <li>Dominion Diamond Corporation</li>
  1544. <li>Fura Gems Inc.</li>
  1545. <li>Pala International Inc.</li>
  1546. <li>Zales Corporation</li>
  1547. <li>Debswana Diamond Company (Pty) Limited</li>
  1548. <li>PJSC ALROSA</li>
  1549. <li>Anglo American PLC</li>
  1550. <li>Lucara Diamond Corp.</li>
  1551. <li>Gitanjali Gems Ltd (India)</li>
  1552. <li>Rockwell Diamonds Inc.</li>
  1553. <li>Manihar Group of Gems &amp; Jewellery</li>
  1554. <li>Pangolin Diamonds Corporation</li>
  1555. <li>Gem Diamonds Limited</li>
  1556. <li>KGK Group</li>
  1557. <li>Mountain Province Diamonds Inc.</li>
  1558. <li>MIF Gems Co Ltd.</li>
  1559. <li>Blue Nile</li>
  1560. <li>Trans Hex Group Ltd.</li>
  1561. <li>De Beers Jewellers Ltd</li>
  1562. <li>ALROSA</li>
  1563. <li>Merlin Diamonds Limited</li>
  1564. <li>Botswana Diamonds P.L.C</li>
  1565. <li>Tiffany &amp; Co.</li>
  1566. <li>Rio Tinto Diamonds</li>
  1567. </ul>
  1568. <p>
  1569.                  <b>Recent Industry Developments</b>
  1570.                </p>
  1571. <ul type="disc">
  1572. <li>
  1573.                    <b>September 2025</b> – <i>Malabar Gold &amp; Diamonds</i> unveiled the <i>&#8216;Vyana&#8217; Gemstone Collection</i> during a grand launch event in Mysore, attended by prominent guests and company executives. The collection, crafted in both 18kt and 22kt gold, combines diamond-like brilliance with vibrant gemstones. Its lightweight and fluid designs cater to modern Indian women seeking elegance that blends tradition with contemporary aesthetics.</li>
  1574. <li>
  1575.                    <b>August 2025</b> – <i>Columbia Gem House</i> introduced a new collection of untreated, traceable rubies and sapphires sourced from Tanzania&#8217;s Winza region and nearby mining zones. The collection showcases gemstones in vivid pinks, saturated purples, fuchsia, padparadscha, and authentic ruby tones, many featuring unique two-tone zoning and bicolor effects. This initiative emphasizes the brand&#8217;s commitment to traceability and natural beauty in gemstone sourcing.</li>
  1576. <li>
  1577.                    <b>January 2025</b> – <i>De Beers</i> launched its <i>Lab-Grown Diamond Collection</i>, marking a major milestone in sustainable luxury. The collection aims to expand access to affordable and ethically sourced diamonds, addressing growing demand among eco-conscious consumers. The initiative positions lab-grown diamonds as a viable alternative within the premium jewelry market while reinforcing De Beers&#8217; leadership in responsible innovation.</li>
  1578. <li>
  1579.                    <b>March 2024</b> – <i>Gemfields</i> expanded its <i>Ethical Gemstone Sourcing Initiatives</i>, reinforcing its dedication to transparency and responsible mining. The program strengthens traceability across the supply chain and sets new standards for sustainability in the colored gemstone market. This move is expected to boost consumer trust and appeal to buyers prioritizing ethical sourcing and environmental accountability.</li>
  1580. </ul>
  1581. <p>
  1582.                  <b>Reasons to Purchase this Report:</b>
  1583.                </p>
  1584. <ul type="disc">
  1585. <li>Gain a comprehensive understanding of the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion).</li>
  1586. <li>Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region.</li>
  1587. <li>Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years.</li>
  1588. <li>Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning.</li>
  1589. <li>Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions.</li>
  1590. <li>Benefit from Porter&#8217;s Five Forces analysis and Value Chain insights to evaluate various market perspectives and competitive dynamics.</li>
  1591. <li>Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years.</li>
  1592. </ul>
  1593. <p>
  1594.                  <b>Browse the report and understand how it can benefit your business strategy  &#8211; <a href="https://www.credenceresearch.com/report/gemstones-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/gemstones-market</a></b>
  1595.                </p>
  1596. <p>
  1597.                  <b>Discover additional reports tailored to your industry needs</b>
  1598.                </p>
  1599. <p>
  1600.                  <b>Diamond Studded Jewellery Market &#8211; <a href="https://www.credenceresearch.com/report/diamond-studded-jewellery-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/diamond-studded-jewellery-market</a></b>
  1601.                </p>
  1602. <p>
  1603.                  <b>Jewellery Box Packaging Market &#8211; <a href="https://www.credenceresearch.com/report/jewellery-box-packaging-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/jewellery-box-packaging-market</a></b>
  1604.                </p>
  1605. <p>
  1606.                  <b>India Gemstone and Jewellery Market &#8211; <a href="https://www.credenceresearch.com/report/india-gemstone-and-jewellery-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/india-gemstone-and-jewellery-market</a></b>
  1607.                </p>
  1608. <p>
  1609.                  <b>Jewellery Store Management Software Market &#8211; <a href="https://www.credenceresearch.com/report/jewellery-store-management-software-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/jewellery-store-management-software-market</a></b>
  1610.                </p>
  1611. <p>
  1612.                  <b>Imitation Jewellery Market &#8211; <a href="https://www.credenceresearch.com/report/imitation-jewellery-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/imitation-jewellery-market</a></b>
  1613.                </p>
  1614. <p>
  1615.                  <b>Demi Fine Jewellery Market &#8211; <a href="https://www.credenceresearch.com/report/demi-fine-jewellery-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/demi-fine-jewellery-market</a></b>
  1616.                </p>
  1617. <p>
  1618.                  <b>Costume Jewellery Market &#8211; <a href="https://www.credenceresearch.com/report/costume-jewellery-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/costume-jewellery-market</a></b>
  1619.                </p>
  1620. <p>
  1621.                  <b>Luxury Goods Market &#8211; <a href="https://www.credenceresearch.com/report/luxury-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/luxury-market</a></b>
  1622.                </p>
  1623. <p>
  1624.                  <b>Follow Us:</b>
  1625.                </p>
  1626. <p>
  1627.                  <a href="https://www.linkedin.com/company/credenceresearch/" target="_blank" rel="nofollow">https://www.linkedin.com/company/credenceresearch/</a>
  1628.                </p>
  1629. <p>
  1630.                  <a href="https://x.com/CredenceResearc" target="_blank" rel="nofollow">https://x.com/CredenceResearc</a>
  1631.                </p>
  1632. <p>
  1633.                  <a href="https://www.facebook.com/CredenceResearch" target="_blank" rel="nofollow">https://www.facebook.com/CredenceResearch</a>
  1634.                </p>
  1635. <p>
  1636.                  <b>About Us:</b>
  1637.                </p>
  1638. <p>
  1639.                  <a href="https://www.credenceresearch.com/" target="_blank" rel="nofollow">Credence Research</a> is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives.</p>
  1640. <p>
  1641.                  <b>Contact Us</b>
  1642.                </p>
  1643. <p>Credence Research Europe LTD<br /></br>128 City Road, London,<br /></br>EC1V 2NX, UNITED KINGDOM<br /></br>Europe &#8211; +44 7809 866 263<br /></br>North America &#8211; +1 304 308 1216<br /></br>Australia &#8211; +61 4192 46279<br /></br>Asia Pacific &#8211; +81 5050 50 9250<br /></br>+64 22 017 0275<br /></br>India &#8211; +91 6232 49 3207<b><br /></br><a href="mailto:sales@credenceresearch.com" target="_blank" rel="nofollow">sales@credenceresearch.com</a><br /></br><a href="https://www.credenceresearch.com/" target="_blank" rel="nofollow">www.credenceresearch.com</a></b></p>
  1644. <p>Logo &#8211; <a href="https://mma.prnewswire.com/media/2562161/5559766/Credence_Research_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2562161/5559766/Credence_Research_Logo.jpg</a></p>
  1645. <p id="PURL">
  1646.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96685&amp;sd=2025-10-13"></img> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/gemstones-market-to-reach-usd-101-01-billion-by-2032--growing-at-an-6-3-cagr--credence-research-302582438.html" target="_blank">https://www.prnewswire.co.uk/news-releases/gemstones-market-to-reach-usd-101-01-billion-by-2032&#8211;growing-at-an-6-3-cagr&#8211;credence-research-302582438.html</a></p>
  1647. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96685&amp;Transmission_Id=202510131549PR_NEWS_EURO_ND__EN96685&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  1648. ]]></content:encoded>
  1652. </item>
  1653. <item>
  1654. <title>Algae Products Market to Reach USD 9.7Billion by 2032, Growing At An 7% CAGR &#8211; Credence Research</title>
  1655. <link>https://thenewsthisweek.co.uk/algae-products-market-to-reach-usd-9-7billion-by-2032-growing-at-an-7-cagr-credence-research-27208/</link>
  1657. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  1658. <pubDate>Mon, 13 Oct 2025 19:05:00 +0000</pubDate>
  1659. <category><![CDATA[Brand Post]]></category>
  1660. <guid isPermaLink="false">https://thenewsthisweek.co.uk/algae-products-market-to-reach-usd-9-7billion-by-2032-growing-at-an-7-cagr-credence-research-27208/</guid>
  1661.  
  1662. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="115" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/algae-products-market-to-reach-usd-9-7billion-by-2032-growing-at-an-7-cagr-credence-research.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Algae Products Market to Reach USD 9.7Billion by 2032, Growing At An 7% CAGR - Credence Research" decoding="async" loading="lazy" /></div>Credence Research Unveils Comprehensive Analysis Projecting Market to Reach USD 9,728.83 Million by 2032, Driven by Rising Health Consciousness and Environmental Sustainability Imperatives PUNE, India, Oct. 13, 2025 /PRNewswire/ &#8212; The global algae products market is experiencing a transformative phase, characterized by unprecedented growth momentum and expanding applications across diverse industries including food and beverages, nutraceuticals, [&#8230;]]]></description>
  1663. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="115" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/algae-products-market-to-reach-usd-9-7billion-by-2032-growing-at-an-7-cagr-credence-research.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Algae Products Market to Reach USD 9.7Billion by 2032, Growing At An 7% CAGR - Credence Research" decoding="async" loading="lazy" /></div><p>
  1664.                  <i>Credence Research Unveils Comprehensive Analysis Projecting Market to Reach USD 9,728.83 Million by 2032, Driven by Rising Health Consciousness and Environmental Sustainability Imperatives</i>
  1665.                </p>
  1666. <p>
  1667.                  <span class="legendSpanClass">PUNE, India</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; The global algae products market is experiencing a transformative phase, characterized by unprecedented growth momentum and expanding applications across diverse industries including food and beverages, nutraceuticals, cosmetics, biofuels, and animal feed. According to a comprehensive analysis by Credence Research, <a href="https://www.credenceresearch.com/report/algae-products-market" target="_blank" rel="nofollow">the algae products market size</a> was valued at USD 5,291.84 million in 2024 and is anticipated to reach USD 9,728.83 million by 2032, at a CAGR of 7.00% during the forecast period. This significant expansion reflects the accelerating global transition toward plant-based nutrition, sustainable protein alternatives, and environmentally conscious consumer choices.</p>
  1668. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
  1669. <p>
  1670.                    <a href="https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.html" target="_blank" rel="nofollow"><br />
  1671.                      <img decoding="async" src="https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg" title="Credence Research Logo (PRNewsfoto/Credence Research Inc.)" alt="Credence Research Logo (PRNewsfoto/Credence Research Inc.)"></img><br />
  1672.                    </a>
  1673.                  </p>
  1674. </p></div>
  1675. <p>
  1676.                  <b>Market Overview</b>
  1677.                </p>
  1678. <p>The algae products market encompasses a broad spectrum of offerings derived from both microalgae and macroalgae species, with spirulina, chlorella, astaxanthin, and various seaweed-based hydrocolloids representing the most commercially significant segments. The market&#8217;s robust trajectory is underpinned by multiple converging trends, including the rising prevalence of health-conscious consumers seeking natural nutritional supplements, the cosmetics industry&#8217;s pivot toward sustainable marine-derived ingredients, and the agricultural sector&#8217;s growing adoption of algae-based biofertilizers and animal feed additives.</p>
  1679. <p>Spirulina holds a dominant 39.11% market share in 2024, supported by established consumer trust, extensive clinical research validating its nutritional value, and robust distribution networks across multiple channels. The blue-green microalga&#8217;s complete amino acid profile and 55-70% protein content make it particularly attractive to health and fitness-focused consumer segments. Simultaneously, chlorella exhibits the highest growth rate with a 15.52% CAGR through 2030, primarily driven by increased recognition of its detoxification properties, immune-boosting capabilities, and higher concentrations of certain vitamins and amino acids.</p>
  1680. <p>The market landscape has witnessed significant innovation momentum, with major industry players investing substantially in research and development, strategic partnerships, and production capacity expansions. In August 2025, Corbion and Kuehnle AgroSystems announced a strategic partnership to develop and commercialize high-quality, natural astaxanthin derived from non-GMO heterotrophic algae, combining KAS&#8217;s advanced fermentation platform with Corbion&#8217;s industrial production capabilities and regulatory expertise. This collaboration exemplifies the industry&#8217;s focus on delivering sustainable, science-based solutions for both human nutrition and aquaculture applications.</p>
  1681. <p>dsm-firmenich has been at the forefront of advancing algae-based omega-3 solutions, successfully transitioning its life&#8217;sOMEGA portfolio from fish oil to algal sources throughout 2024. The company launched life&#8217;sOMEGA O3O2O in early 2024, featuring an EPA:DHA ratio of 1.5:1 that mirrors standard fish oil while offering twice the potency in a vegan, microalgal-based format produced through proprietary precision fermentation. In October 2024, dsm-firmenich expanded its advanced life&#8217;s portfolio with life&#8217;sDHA B54-0100, a naturally potent DHA algal oil with exceptional sensory appeal, while announcing plans to launch two new highly potent, EPA-rich products in early 2025.</p>
  1682. <p>
  1683.                  <b><br />
  1684.                    <i>Browse the report and understand how it can benefit your business strategy &#8211;</i><br />
  1685.                    <u><br />
  1686.                      <a href="https://www.credenceresearch.com/report/algae-products-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/algae-products-market</a><br />
  1687.                    </u><br />
  1688.                  </b>
  1689.                </p>
  1690. <p>
  1691.                  <b>Key Growth Determinants</b>
  1692.                </p>
  1693. <p>
  1694.                  <b>Escalating Consumer Demand for Plant-Based Protein and Sustainable Nutrition</b>
  1695.                </p>
  1696. <p>The global shift toward plant-based diets and alternative protein sources constitutes a fundamental driver propelling the algae products market forward. Consumers increasingly prioritize sustainable, natural, and ethically sourced nutritional solutions that align with environmental conservation values and personal health objectives. Spirulina and chlorella have emerged as compelling plant-based protein alternatives, offering complete amino acid profiles, superior nutrient density, and environmental production advantages compared to conventional animal-based proteins.</p>
  1697. <p>Cyanotech Corporation, a world leader in microalgae technology, reported a 15% increase in net sales during the first quarter of fiscal year 2025, primarily driven by increased Astaxanthin sales, and launched Hawaiian Spirulina gummies in May 2024 to expand its product portfolio and meet growing consumer demand for convenient supplementation formats. The nutraceutical segment accounts for 66.5% of the chlorella market, driven by growing consumer curiosity about nutrition-rich foods and chlorella&#8217;s properties that integrate metabolism, balance the body, and regulate immune effects. This sustained consumer interest reflects broader demographic shifts toward preventive health approaches and willingness to invest in premium nutritional products.</p>
  1698. <p>
  1699.                  <b>Technological Advancements in Algae Cultivation and Processing</b>
  1700.                </p>
  1701. <p>Breakthrough innovations in algae cultivation technologies, particularly photobioreactors and controlled fermentation systems, have dramatically enhanced production efficiency, reduced operational costs, and improved product quality consistency. Companies like Algenie are combining photobioreactor design with AI-driven strain optimization to convert CO2 into valuable raw materials for applications spanning plastics, food, biofuels, and textiles, effectively solving economic and scalability challenges that previously constrained algae-based alternatives.</p>
  1702. <p>Swedish Algae Factory secured €3 million in April 2025 to expand production of its patented material Algica, developed from algae shells and already incorporated into more than 60 personal care products including L:A Bruket&#8217;s 281 protective fluid and Verso&#8217;s daily SPF 50. Recent microencapsulation technology developments have enhanced powder stability, reduced oxidation, resulted in longer shelf life, and preserved bioactive compounds, addressing critical quality parameters for commercial applications. These technological progressions enable mass production while maintaining stringent quality standards, facilitating broader market penetration across food, pharmaceutical, cosmetic, and industrial sectors. The advancement of closed-loop farming systems and enhanced extraction techniques further contributes to efficient results with lower costs, making algae products increasingly competitive against conventional alternatives.</p>
  1703. <p>
  1704.                  <b>Growing Applications in Cosmetics and Personal Care Industries</b>
  1705.                </p>
  1706. <p>The cosmetics and personal care sector has embraced algae-derived ingredients as premium, sustainable alternatives that deliver compelling functional benefits including antioxidant protection, moisturization, anti-inflammatory effects, and anti-aging properties. Algae and seaweeds are gaining traction as part of the larger &#8220;blue economy&#8221; movement, offering bioactive compounds ranging from antioxidants to polysaccharides and peptides, packed with vitamins, amino acids, and minerals.</p>
  1707. <p>Popular species including spirulina, chlorella, brown seaweeds, and various red algae have grown significantly in cosmetic applications throughout 2024. The sustainable credentials of algae cultivation, combined with demonstrated efficacy in clinical studies, resonate strongly with environmentally conscious consumers prioritizing natural, eco-friendly ingredients and supporting brands committed to reducing environmental footprints.</p>
  1708. <p>Companies are leveraging algae&#8217;s unique light-altering, absorptive, releasing, and blocking properties unmatched by synthetic materials to create differentiated product formulations. Swedish Algae Factory&#8217;s recent research demonstrated that Algica can reduce and replace harmful chemicals in multiple applications including wound care, expanding the ingredient&#8217;s potential beyond traditional cosmetic uses. This convergence of sustainability, functionality, and clean-label appeal positions algae as a cornerstone ingredient for next-generation personal care formulations addressing increasingly sophisticated consumer expectations.</p>
  1709. <p>
  1710.                  <b>Key Growth Barriers</b>
  1711.                </p>
  1712. <p>
  1713.                  <b>High Capital Investment Requirements and Production Infrastructure Costs</b>
  1714.                </p>
  1715. <p>The algae products market faces substantial barriers related to the significant capital expenditures required for establishing commercial-scale production facilities, including specialized photobioreactors, land acquisition, water supply systems, and sophisticated processing equipment. These high initial setup costs particularly deter small and medium enterprises from market entry, potentially limiting innovation diversity and competitive dynamics.</p>
  1716. <p>The additional costs incurred for setting up comprehensive algae farming infrastructure, including controlled environmental systems that maintain optimal growing conditions, harvesting mechanisms, and downstream processing capabilities, create formidable financial obstacles. Production facilities must incorporate advanced technological components such as CO2 delivery systems, precise lighting configurations, temperature control mechanisms, and contamination prevention protocols, each representing substantial investment requirements.</p>
  1717. <p>Furthermore, the specialized nature of algae cultivation necessitates hiring experienced personnel or investing in extensive training programs, adding to operational expenditure burdens. The extended timeframes required to achieve full production capacity and market return on investment can strain financial resources, particularly for emerging companies lacking access to substantial venture capital or corporate backing. These cumulative financial barriers contribute to market concentration among established players with existing infrastructure and capital reserves, potentially limiting the pace of market democratization and geographic expansion.</p>
  1718. <p>
  1719.                  <b>Quality Consistency and Supply Chain Challenges</b>
  1720.                </p>
  1721. <p>Maintaining consistent product quality across production batches presents persistent challenges for algae manufacturers, as microalgae cultivation can be highly sensitive to environmental variables including light intensity, temperature fluctuations, nutrient availability, water quality, and microbial contamination risks. Between July 2024 and November 2024, Cyanotech systematically procured 37 best-selling spirulina and greens powder products sold to U.S. consumers and conducted comprehensive testing that revealed variations in heavy metal content, underscoring quality control challenges across the industry.</p>
  1722. <p>The biological nature of algae production means that even minor deviations in cultivation parameters can significantly impact biomass yield, nutritional composition, bioactive compound concentrations, and sensory characteristics such as taste and odor. Natural astaxanthin commands higher prices than synthetic versions specifically due to better bioavailability and consumer preference for natural sources, yet achieving consistent natural production at commercial scale remains technically demanding.</p>
  1723. <p>Supply chain complexities are compounded by seasonal variations affecting outdoor cultivation systems, the perishability of fresh algae biomass requiring rapid processing, and the specialized storage and transportation conditions necessary to preserve bioactive compounds. Regulatory compliance across different geographic markets adds further complexity, as products must meet varying purity standards, labeling requirements, and health claim substantiation thresholds. These quality and supply chain challenges necessitate substantial investments in quality management systems, analytical testing capabilities, and supply chain optimization, creating operational complexity that can impede rapid market scaling.</p>
  1724. <p>
  1725.                  <b><br />
  1726.                    <i>Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today &#8211;</i><br />
  1727.                  </b><br />
  1728.                  <a href="https://www.credenceresearch.com/report/algae-products-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/algae-products-market</a>   </p>
  1729. <p>
  1730.                  <b>Key Market Trends</b>
  1731.                </p>
  1732. <p>
  1733.                  <b>Strategic Partnerships and Vertical Integration</b>
  1734.                </p>
  1735. <p>The algae products market is witnessing an acceleration of strategic collaborations between ingredient manufacturers, food and beverage brands, cosmetics companies, and technology providers seeking to secure supply chains and co-develop innovative applications. In August 2024, SourceOne Global Partners announced a strategic partnership with Qualitas Health to introduce U.S.-produced microalgae omega-3 ingredients trademarked AlmegaPL to the global marketplace, leveraging SourceOne&#8217;s sales, marketing, and distribution infrastructure to serve leading nutraceutical, functional food, beverage, and animal nutrition brands.</p>
  1736. <p>This collaboration positions both companies as pioneers in the emerging plant-based omega-3 industry with a focus on environmental sustainability and overcoming omega-3 supply chain concerns. Major food companies, beauty conglomerates, and feed giants are increasingly partnering with algae specialists to secure reliable ingredient supplies and co-develop differentiated product formulations that meet evolving consumer preferences.</p>
  1737. <p>In 2024, dsm-firmenich successfully partnered with Korea Eundan to transition the company&#8217;s entire line of fish-oil-based omega-3 products to an elevated microalgal-based alternative, completing the portfolio transformation before the end of 2024 by leveraging cross-functional expertise including sales, regulatory, application, sensory, quality, and production teams.</p>
  1738. <p>The trend toward vertical integration is also gaining momentum, with companies seeking to control more elements of the value chain from strain selection and cultivation through extraction, formulation, and market distribution, ensuring quality consistency and margin optimization throughout the production process.</p>
  1739. <p>
  1740.                  <b>Expansion of Algae-Based Functional Foods and Beverages</b>
  1741.                </p>
  1742. <p>Food and beverage manufacturers are increasingly incorporating algae ingredients into mainstream product categories to deliver enhanced nutritional profiles and meet consumer demand for functional benefits. The food and beverages segment held a dominant 30% share in 2024, with growth driven by a surge in consumer health consciousness around plant-based diets and the desire for products that offer additional health benefits beyond basic nutrition.</p>
  1743. <p>In October 2024, Protoga Biotech, a Chinese company pioneering microalgae fermentation, announced the launch of a microalgae milk product that represents a significant innovation in plant-based dairy alternatives. Powder formulations hold a 39.20% market share in 2024, supported by established consumer preferences and the versatility to integrate into smoothies, protein shakes, and various food products while maintaining lower per-serving costs.</p>
  1744. <p>Capsule formats demonstrate strong growth with a 14.54% CAGR, driven by convenience and improved palatability that addresses common taste and odor concerns associated with algae products. The combination supplements category, which combines multiple algae species to offer comprehensive nutrition profiles, allows manufacturers to create distinct product formulations that differentiate their offerings in increasingly competitive markets. This trend reflects the broader movement toward personalized nutrition and functional foods that address specific health concerns including immunity support, cardiovascular health, cognitive function, and metabolic wellness.</p>
  1745. <p>
  1746.                  <b>Emergence of Carbon Capture and Circular Economy Applications</b>
  1747.                </p>
  1748. <p>Algae&#8217;s remarkable capacity for carbon dioxide sequestration is driving new applications in climate change mitigation and circular economy initiatives, positioning algae cultivation as a dual-purpose activity that generates valuable biomass while addressing environmental challenges. Companies like Anuala are focusing on carbon capture using algae technology, while NeoEarth develops high-yield natural microalgae strains tailored for producers seeking to improve productivity through genetic improvements that elevate production speed, robustness, and specific targets such as concentration and color.</p>
  1749. <p>Swedish Algae Factory is striving toward production that is as environmentally-friendly as possible, using recycled nutrients and carbon dioxide for algae growth, with organic by-products used to produce biogas and eco-fertilizers that may eventually be incorporated into animal feeds, cosmetics, and food products. VODORASLO develops domestic photobioreactor devices that utilize algae for air purification, leveraging photosynthesis to consume gases such as CO2, NOX, SO2, and larger pollutants like PM2.5, PM10, and VOCs while producing oxygen and biomass that can be repurposed as natural fertilizer, biodegradable packaging, food supply, pigment, or cosmetics.</p>
  1750. <p>Major industrial sectors including cement production, power generation, and manufacturing are exploring algae cultivation as a carbon mitigation strategy that transforms CO2 emissions into commercially valuable products. This circular economy approach aligns with corporate sustainability commitments, regulatory pressures for emissions reduction, and growing investor expectations for environmental responsibility, creating new revenue streams and market opportunities beyond traditional algae product applications.</p>
  1751. <p>
  1752.                  <b>Key Opportunities</b>
  1753.                </p>
  1754. <p>
  1755.                  <b>Penetration of Emerging Markets with Growing Middle-Class Populations</b>
  1756.                </p>
  1757. <p>Emerging economies across Asia Pacific, Latin America, and Africa present substantial growth opportunities driven by expanding middle-class populations, increasing disposable incomes, rising health awareness, and rapid urbanization that transforms dietary patterns toward premium nutritional products. Asia Pacific held the largest share of 45% in the global market in 2024, driven by rising demand for sustainable bioresources, plant-based functional foods, and advancements in cultivation technologies. China is leading the regional market and is anticipated to capture a share of USD 16.36 billion in 2025, while India is estimated to be worth USD 0.86 billion and Japan is set to be valued at USD 4.83 billion in the same year.</p>
  1758. <p>In June 2023, the Global Red Sea Algae Research Foundation was inaugurated in Kumbakonam, Tamil Nadu, marking a significant step in marine research focusing on red algae applications in pharmaceuticals, food, and biotechnology. Government initiatives across the region are actively promoting algae cultivation and usage across multiple industries including pharmaceuticals, nutraceuticals, cosmetics, and biofuels, further supporting market growth.</p>
  1759. <p>The high demand for algae cultivation across diverse applications, combined with favorable regulatory frameworks encouraging sustainable agriculture and nutrition security, positions emerging markets as critical growth engines for the global algae products industry. Local production capabilities are expanding rapidly, reducing import dependence and improving supply chain resilience while creating employment opportunities in rural and coastal communities.</p>
  1760. <p>
  1761.                  <b>Development of Novel Algae Strains and Bioengineering Applications</b>
  1762.                </p>
  1763. <p>Advances in genetic research, synthetic biology, and strain optimization technologies are enabling the development of novel algae varieties with enhanced productivity, targeted nutritional profiles, improved stress tolerance, and optimized bioactive compound concentrations. Companies like TransAlgae, founded in 2023, are developing multi-purpose algal platforms that use microalgae as cell-based factory systems for producing and naturally encapsulating therapeutic products including hormones, enzymes, vaccines, and insecticides delivered orally through algae pills, animal feed, or crop spraying.</p>
  1764. <p>Edonia, founded in 2023, has developed a proprietary process called Edonization that converts micro-algae biomass including spirulina and chlorella into textured ingredients with meat-like texture and umami flavor profiles without additives or artificial flavorings, secured EUR 2 million in funding. NeoEarth develops augmented algae strains utilizing genetic improvements to elevate production speed, robustness, and specific targets, providing cost-effective biomass for diverse industries including cosmetics, feed, food, and biomaterials.</p>
  1765. <p>These bioengineering innovations enable the creation of specialty algae products tailored for specific applications such as pharmaceutical ingredient production, high-value nutraceutical compounds, sustainable textile fibers, and biodegradable packaging materials. The intersection of biotechnology and algae cultivation opens entirely new market segments beyond traditional food and feed applications, potentially revolutionizing industries ranging from fashion to medicine. Investment in R&amp;D infrastructure, intellectual property development, and regulatory pathway navigation will be critical for companies seeking to capitalize on these emerging biotechnology opportunities.</p>
  1766. <p>
  1767.                  <b>Expansion in Alternative Protein and Sustainable Aquaculture Sectors</b>
  1768.                </p>
  1769. <p>The global protein transition driven by population growth, resource constraints, and environmental concerns creates substantial opportunities for algae products as sustainable feed ingredients for aquaculture, animal husbandry, and direct human consumption as meat alternatives. Astaxanthin is widely recognized both for its human health benefits and as a key feed ingredient for salmon and other aquaculture species, with Corbion and KAS developing an esterified form rich in the most bioavailable isomer, delivering superior antioxidant performance, enhanced stability, and fat solubility designed for both human and animal nutrition markets.</p>
  1770. <p>Corbion secured regulatory approvals in July 2025 to sell its algae-derived omega-3 DHA products in China, one of the world&#8217;s largest and fastest-growing aquaculture markets, representing a significant market access milestone. Spirulina produces 15 times more protein per acre than beef, corn, and soybeans while using 7 times less water to produce it, offering compelling sustainability advantages for addressing global protein demands. The aquaculture industry, facing challenges related to fish meal sustainability and omega-3 supply constraints, is increasingly adopting algae-based feed formulations that reduce environmental impact while maintaining nutritional quality and supporting fish health and pigmentation.</p>
  1771. <p>The alternative protein sector for human consumption is exploring algae as a viable ingredient for plant-based meat analogues, protein beverages, and nutritional bars that can compete effectively with conventional animal proteins on taste, texture, nutritional density, and price points. These applications collectively represent multi-billion dollar market opportunities that align with global sustainability objectives and resource efficiency imperatives.</p>
  1772. <p>
  1773.                  <b>Segmentation</b>
  1774.                </p>
  1775. <p>By Type</p>
  1776. <ul type="disc">
  1777. <li>Lipids</li>
  1778. <li>Carrageenan</li>
  1779. <li>Alginate</li>
  1780. <li>Algal Protein</li>
  1781. <li>Others</li>
  1782. </ul>
  1783. <p>
  1784.                  <b>By Form</b>
  1785.                </p>
  1786. <ul type="disc">
  1787. <li>Solid</li>
  1788. <li>Liquid</li>
  1789. </ul>
  1790. <p>
  1791.                  <b>By Source</b>
  1792.                </p>
  1793. <ul type="disc">
  1794. <li>Green Algae</li>
  1795. <li>Brown Algae</li>
  1796. <li>Blue-Green Algae</li>
  1797. <li>Red Algae</li>
  1798. <li>Others</li>
  1799. </ul>
  1800. <p>
  1801.                  <b>By Processing</b>
  1802.                </p>
  1803. <ul type="disc">
  1804. <li>Food &amp; Beverages</li>
  1805. <li>Nutraceuticals &amp; Dietary Supplements</li>
  1806. <li>Personal Care</li>
  1807. <li>Feed</li>
  1808. <li>Others</li>
  1809. </ul>
  1810. <p>
  1811.                  <b> Based on Region:</b>
  1812.                </p>
  1813. <ul type="disc">
  1814. <li>North America</li>
  1815. <ul type="circle">
  1816. <li>United States</li>
  1817. <li>Canada</li>
  1818. </ul>
  1819. <li>Europe</li>
  1820. <ul type="circle">
  1821. <li>United Kingdom</li>
  1822. <li>Germany</li>
  1823. <li>France</li>
  1824. </ul>
  1825. <li>Asia-Pacific</li>
  1826. <ul type="circle">
  1827. <li>China</li>
  1828. <li>India</li>
  1829. <li>Japan</li>
  1830. </ul>
  1831. <li>Latin America</li>
  1832. <ul type="circle">
  1833. <li>Brazil</li>
  1834. <li>Mexico</li>
  1835. </ul>
  1836. <li>Middle East &amp; Africa</li>
  1837. <ul type="circle">
  1838. <li>South Africa</li>
  1839. <li>United Arab Emirates</li>
  1840. </ul>
  1841. </ul>
  1842. <p>
  1843.                  <b>Regional Analysis</b>
  1844.                </p>
  1845. <p>The global algae products market exhibits significant regional variation in growth patterns, consumer preferences, regulatory frameworks, and production capabilities that shape competitive dynamics and strategic priorities. Asia Pacific dominated the market with a 53.25% share in 2024, valued at USD 22.30 billion, driven by the region&#8217;s extensive coastlines, favorable climatic conditions for algae cultivation, established seaweed consumption traditions, and rapidly growing demand for plant-based nutrition and sustainable ingredients.</p>
  1846. <p>China leads regional growth with its massive consumer base, government support for biotechnology industries, expanding aquaculture sector, and increasing health consciousness among urban populations, while Japan contributes substantially through its mature market for algae-based foods and advanced research capabilities. India represents an emerging growth market supported by government initiatives promoting sustainable agriculture, expanding middle-class populations seeking premium nutritional products, and growing research infrastructure exemplified by the June 2023 inauguration of the Global Red Sea Algae Research Foundation in Tamil Nadu.</p>
  1847. <p>North America is projected to experience significant growth driven by increasing demand for plant-derived proteins, greater use of algae in functional foods and nutraceuticals, strong consumer awareness regarding health and sustainability issues, and robust regulatory frameworks supporting novel ingredient approvals.</p>
  1848. <p>The region benefits from substantial R&amp;D investment, advanced biotechnology capabilities, and established distribution channels for specialty nutritional products. Europe maintains a strong market position characterized by stringent sustainability standards, consumer preference for clean-label products, advanced cosmetics industries incorporating marine ingredients, and supportive regulatory policies promoting circular economy principles and carbon reduction technologies.</p>
  1849. <p>Latin America and Africa represent nascent but promising markets where growing urbanization, rising disposable incomes, increasing nutrition awareness, and abundant natural resources for algae cultivation create favorable conditions for market development, though infrastructure limitations and regulatory frameworks require continued development to fully unlock regional potential.</p>
  1850. <p>
  1851.                  <b>Credence Research&#8217;s Competitive Landscape Analysis</b>
  1852.                </p>
  1853. <p>Credence Research&#8217;s comprehensive competitive landscape analysis examines the strategic positioning, market share dynamics, innovation pipelines, and competitive strategies of leading players across the algae products value chain. The analysis identifies key market participants including Archer Daniels Midland Company, Cargill Incorporated, BASF SE, Koninklijke DSM N.V. (now dsm-firmenich), Corbion, Cyanotech Corporation, DuPont de Nemours Inc., and emerging innovators such as Swedish Algae Factory, Qualitas Health, and Algenie that are reshaping market dynamics through technological innovation and novel business models.</p>
  1854. <p>The competitive landscape is characterized by a combination of large, vertically integrated multinational corporations leveraging scale advantages, production efficiency, and global distribution networks, alongside specialized biotechnology firms focusing on proprietary strains, advanced cultivation technologies, and high-value niche applications. Strategic activities including partnerships, acquisitions, capacity expansions, and new product launches are analyzed to provide insights into competitive strategies and market evolution trajectories.</p>
  1855. <p>The analysis reveals that competitive advantage increasingly derives from intellectual property portfolios protecting novel strains and production processes, regulatory expertise enabling market access across diverse geographies, end-to-end capabilities spanning from cultivation through formulation and market distribution, and sustainability credentials that resonate with environmentally conscious consumers and corporate customers. Credence Research&#8217;s assessment also examines emerging competitive threats from startups leveraging synthetic biology, precision fermentation, and artificial intelligence for strain optimization, which may disrupt established market positions and create new value chain configurations.</p>
  1856. <p>The competitive landscape analysis provides strategic intelligence supporting informed decision-making regarding market entry strategies, partnership opportunities, investment priorities, and competitive positioning for stakeholders across the algae products ecosystem..</p>
  1857. <p>
  1858.                  <b><br />
  1859.                    <i>Tailor the report to align with your specific business needs and gain targeted insights. Request Here &#8211; <a href="https://www.credenceresearch.com/report/algae-products-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/algae-products-market</a></i><br />
  1860.                  </b>
  1861.                </p>
  1862. <p>
  1863.                  <b>Key Player Analysis</b>
  1864.                </p>
  1865. <ul type="disc">
  1866. <li>Algae Systems LLC</li>
  1867. <li>Euglena Co.</li>
  1868. <li>Cyanotech Corporation</li>
  1869. <li>Cargill</li>
  1870. <li>DSM</li>
  1871. <li>Kerry</li>
  1872. <li>Corbion</li>
  1873. <li>BIOPROCESS ALGAE, LLC.</li>
  1874. <li>BASF</li>
  1875. </ul>
  1876. <p>
  1877.                  <b> Recent Industry Developments</b>
  1878.                </p>
  1879. <ul type="disc">
  1880. <li>
  1881.                    <b>May 2025</b> – The U.S. FDA approved <i>Galdieria extract blue</i> as a color additive exempt from certification. Derived from unicellular red algae <i>Galdieria sulphuraria</i>, this approval broadens the range of natural colorants available for food manufacturers and validates the use of algae-derived ingredients in mainstream applications.</li>
  1882. <li>
  1883.                    <b>October 2024</b> – <i>DSM-Firmenich</i> launched <i>life&#8217;s DHA B54-0100</i>, a high-potency algal oil containing 545 mg DHA and 80 mg EPA per gram. This innovation enables smaller supplement capsules and addresses global omega-3 deficiency. The launch marks a major advancement in algae-based omega-3 technology and supports the company&#8217;s growth in North American markets.</li>
  1884. <li>
  1885.                    <b>October 2024</b> – <i>Algiecel</i> secured EUR 6.5 million in equity funding to scale its microalgae production for feed and food industries. The company targets CO₂-emitting industries as bioreactor feedstock sources while producing high-value biomass and bio-oil for commercial applications.</li>
  1886. <li>
  1887.                    <b>September 2024</b> – Two U.S. firms, <i>Algae Cooking Club</i> and <i>Spotlight Foods</i>, introduced cooking oils derived from microalgae, representing a breakthrough in sustainable food technology. Both companies employ fermentation processes using plant-based sugars from sugarcane to convert microalgae into edible oil within days, reducing resource use compared to conventional vegetable oils.</li>
  1888. <li>
  1889.                    <b>August 2024</b> – French startup <i>Edonia</i> raised USD 2.19 million in a funding round led by <i>Asterion Ventures</i> to accelerate its microalgae-based meat alternatives. The investment supports commercialization of products using microalgae such as spirulina and chlorella, recognized for their sustainability and nutritional value.</li>
  1890. <li>
  1891.                    <b>April 30, 2024</b> – <i>Archer-Daniels-Midland (ADM)</i> announced that its global regenerative agriculture program expanded to over 2.8 million acres in 2023, surpassing its 2 million-acre target. The company now aims for 3.5 million regenerative acres in 2024 and has raised its 2025 goal from 4 million to 5 million acres globally.</li>
  1892. <li>
  1893.                    <b>April 23, 2024</b> – <i>Caldic</i> announced a partnership with <i>Gold Coast Ingredients</i> to strengthen its presence in the flavoring market across the DACH region, enhancing its natural ingredient portfolio.</li>
  1894. </ul>
  1895. <p>
  1896.                  <b>Reasons to Purchase this Report:</b>
  1897.                </p>
  1898. <ul type="disc">
  1899. <li>Gain a comprehensive understanding of the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion).</li>
  1900. <li>Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region.</li>
  1901. <li>Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years.</li>
  1902. <li>Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning.</li>
  1903. <li>Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions.</li>
  1904. <li>Benefit from Porter&#8217;s Five Forces analysis and Value Chain insights to evaluate various market perspectives and competitive dynamics.</li>
  1905. <li>Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years.</li>
  1906. </ul>
  1907. <p>
  1908.                  <b>Browse the report and understand how it can benefit your business strategy – <a href="https://www.credenceresearch.com/report/algae-products-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/algae-products-market</a></b>
  1909.                </p>
  1910. <p>
  1911.                  <b>Discover additional reports tailored to your industry needs</b>
  1912.                </p>
  1913. <p>Omega 3 Ingredients Market<b> &#8211; <a href="https://www.credenceresearch.com/report/omega-3-ingredients-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/omega-3-ingredients-market</a></b> </p>
  1914. <p>
  1915.                  <b>Cookie and Wafer Market</b><br />
  1916.                  <b> &#8211; <a href="https://www.credenceresearch.com/report/cookie-and-wafer-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/cookie-and-wafer-market</a></b> </p>
  1917. <p>
  1918.                  <b>Specialty Coffee Market</b><br />
  1919.                  <b> &#8211; <a href="https://www.credenceresearch.com/report/specialty-coffee-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/specialty-coffee-market</a></b> </p>
  1920. <p>
  1921.                  <b>Egg Phosphatidylcholine Market</b><br />
  1922.                  <b> &#8211; <a href="https://www.credenceresearch.com/report/egg-phosphatidylcholine-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/egg-phosphatidylcholine-market</a></b> </p>
  1923. <p>
  1924.                  <b>Shrimp Market</b><br />
  1925.                  <b> &#8211; <a href="https://www.credenceresearch.com/report/shrimp-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/shrimp-market</a></b> </p>
  1926. <p>
  1927.                  <b>Feed Micronutrients Market</b><br />
  1928.                  <b> &#8211; <a href="https://www.credenceresearch.com/report/feed-micronutrients-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/feed-micronutrients-market</a></b> </p>
  1929. <p>
  1930.                  <b>Food Aroma Market</b><br />
  1931.                  <b> &#8211; <a href="https://www.credenceresearch.com/report/food-aroma-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/food-aroma-market</a></b> </p>
  1932. <p>
  1933.                  <b>Food Antimicrobials Market</b><br />
  1934.                  <b>&#8211; <a href="https://www.credenceresearch.com/report/food-antimicrobials-market" target="_blank" rel="nofollow">https://www.credenceresearch.com/report/food-antimicrobials-market</a></b> </p>
  1935. <p>
  1936.                  <b>Follow Us:</b>
  1937.                </p>
  1938. <p>
  1939.                  <a href="https://www.linkedin.com/company/credenceresearch/" target="_blank" rel="nofollow">https://www.linkedin.com/company/credenceresearch/</a>
  1940.                </p>
  1941. <p>
  1942.                  <a href="https://x.com/CredenceResearc" target="_blank" rel="nofollow">https://x.com/CredenceResearc</a>
  1943.                </p>
  1944. <p>
  1945.                  <a href="https://www.facebook.com/CredenceResearch" target="_blank" rel="nofollow">https://www.facebook.com/CredenceResearch</a>
  1946.                </p>
  1947. <p>
  1948.                  <b>About Us:</b>
  1949.                </p>
  1950. <p>
  1951.                  <a href="https://www.credenceresearch.com/" target="_blank" rel="nofollow">Credence Research</a> is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives.</p>
  1952. <p>
  1953.                  <b>Contact Us</b>
  1954.                </p>
  1955. <p>Credence Research Europe LTD<br /></br>128 City Road, London,<br /></br>EC1V 2NX, UNITED KINGDOM<br /></br>Europe &#8211; +44 7809 866 263<br /></br>North America &#8211; +1 304 308 1216<br /></br>Australia &#8211; +61 4192 46279<br /></br>Asia Pacific &#8211; +81 5050 50 9250<br /></br>+64 22 017 0275<br /></br>India &#8211; +91 6232 49 3207<b><br /></br><a href="mailto:sales@credenceresearch.com" target="_blank" rel="nofollow">sales@credenceresearch.com</a><br /></br><a href="https://www.credenceresearch.com/" target="_blank" rel="nofollow">www.credenceresearch.com</a><br /></br></b></p>
  1956. <p>Logo &#8211; <a href="https://mma.prnewswire.com/media/2562161/5559790/Credence_Research_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2562161/5559790/Credence_Research_Logo.jpg</a></p>
  1957. <p id="PURL">
  1958.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96676&amp;sd=2025-10-13"></img> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/algae-products-market-to-reach-usd-9-7billion-by-2032--growing-at-an-7-cagr--credence-research-302582391.html" target="_blank">https://www.prnewswire.co.uk/news-releases/algae-products-market-to-reach-usd-9-7billion-by-2032&#8211;growing-at-an-7-cagr&#8211;credence-research-302582391.html</a></p>
  1959. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96676&amp;Transmission_Id=202510131505PR_NEWS_EURO_ND__EN96676&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  1960. ]]></content:encoded>
  1964. </item>
  1965. <item>
  1966. <title>Innovative and Leading, Gotion High-Tech Empowers Saudi Arabia to Build a Model for Green Zero-Carbon Energy</title>
  1967. <link>https://thenewsthisweek.co.uk/innovative-and-leading-gotion-high-tech-empowers-saudi-arabia-to-build-a-model-for-green-zero-carbon-energy-27210/</link>
  1969. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  1970. <pubDate>Mon, 13 Oct 2025 17:33:00 +0000</pubDate>
  1971. <category><![CDATA[Brand Post]]></category>
  1972. <guid isPermaLink="false">https://thenewsthisweek.co.uk/innovative-and-leading-gotion-high-tech-empowers-saudi-arabia-to-build-a-model-for-green-zero-carbon-energy-27210/</guid>
  1973.  
  1974. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="103" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/innovative-and-leading-gotion-high-tech-empowers-saudi-arabia-to-build-a-model-for-green-zero-carbon-energy.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Innovative and Leading, Gotion High-Tech Empowers Saudi Arabia to Build a Model for Green Zero-Carbon Energy" decoding="async" loading="lazy" /></div>RIYADH, Saudi Arabia, Oct. 13, 2025 /PRNewswire/ &#8212; At the Solar &#38; Storage Live KSA 2025, Gotion High-Tech(SHE:002074) globally debuted two key innovations: the All-Scenario Zero-Carbon Solution and the GOTION GRID Q 20MWh BESS. Designed for scalable and replicable zero-carbon applications, these highlight Gotion&#8217;s commitment to delivering integrated green energy solutions for the Middle East, advancing [&#8230;]]]></description>
  1975. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="103" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/10/innovative-and-leading-gotion-high-tech-empowers-saudi-arabia-to-build-a-model-for-green-zero-carbon-energy.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Innovative and Leading, Gotion High-Tech Empowers Saudi Arabia to Build a Model for Green Zero-Carbon Energy" decoding="async" loading="lazy" /></div><p>
  1976.                  <span class="legendSpanClass">RIYADH, Saudi Arabia</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; At the Solar &amp; Storage Live KSA 2025, Gotion High-Tech(SHE:002074) globally debuted two key innovations: the All-Scenario Zero-Carbon Solution and the GOTION GRID Q 20MWh BESS. Designed for scalable and replicable zero-carbon applications, these highlight Gotion&#8217;s commitment to delivering integrated green energy solutions for the Middle East, advancing Saudi Vision 2030. Gotion also showcased new storage products, including the GOTION EDGE X commercial and industrial system.</p>
  1977. <div id="prni_dvprnejpg1f60left" dir="ltr" style="width: 100%; text-align: left;">
  1978.                  <img decoding="async" id="prnejpg1f60left" title=" " src="https://mma.prnewswire.com/media/2794907/Image.jpg" alt=" " align="middle"></img>
  1979.                </div>
  1980. <p>Gotion&#8217;s All-Scenario Zero-Carbon Solution targets Saudi Arabia&#8217;s transition &#8220;from single-scenario deployment to future city-scale applications,&#8221; including Zero-carbon Park, Heavy Industry, Transportation, Home, Cultural Tourism and Factory. Based on two pillars, the solution achieves carbon reduction, efficiency improvements and cost optimization. Powered by a Digital Energy Platform—the system&#8217;s &#8220;intelligent brain&#8221;—The solution connects energy generation, consumption and management, enabling customized decarbonization across multiple scenarios. The platform also supports value-added services such as electricity trading, operation hosting and carbon management, while offering end-to-end control, ensuring long lifespan, high safety, and high efficiency operation.</p>
  1981. <p>The GOTION GRID Q 20MWh BESS serves as the company&#8217;s dual-engine flagship product for large-scale storage. Its modular design delivers four times the capacity of traditional 5MWh systems, cutting costs by 20% and deployment time by 50%. A hybrid air-liquid cooling system improves energy efficiency by 20%, achieving a 25-year lifespan matching photovoltaic systems. Tailored for Middle Eastern grids and solar energy projects, the system sets a new benchmark for ultra-large energy storage, featuring 400 kWh/m2 energy density with multiple international certifications.</p>
  1982. <p>Backed by its zero-carbon practices, Gotion continues to expand its global green footprint. Several factories in China have achieved zero-carbon certifications through Solar energy plus energy storage (PV+ESS) systems, waste heat recovery, and green logistics. The Xinzhan plant was recognized as a &#8220;Model Carbon-Neutral Factory in Lithium Battery Industry&#8221;. Its zero-carbon anode material plant in Inner Mongolia is powered entirely by renewable electricity with a 1GW solar plant, which will reduce 1.097 million tons of CO2 equivalent annually, proving zero carbon factory is an achievable reality.</p>
  1983. <p>As recognized by Bloomberg NEF (BNEF) and S&amp;P Global as a Tier1 clean energy leader, Gotion High-Tech strives to be not only a provider of innovative green solutions, but also a strategic partner in the Middle East&#8217;s energy transition.</p>
  1984. <p>Photo &#8211; <a href="https://mma.prnewswire.com/media/2794907/Image.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2794907/Image.jpg</a> </p>
  1985. <p id="PURL">
  1986.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96410&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/innovative-and-leading-gotion-high-tech-empowers-saudi-arabia-to-build-a-model-for-green-zero-carbon-energy-302582323.html" target="_blank">https://www.prnewswire.co.uk/news-releases/innovative-and-leading-gotion-high-tech-empowers-saudi-arabia-to-build-a-model-for-green-zero-carbon-energy-302582323.html</a></p>
  1987. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96410&amp;Transmission_Id=202510131333PR_NEWS_EURO_ND__EN96410&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  1988. ]]></content:encoded>
  1992. </item>
  1993. <item>
  1994. <title>Aker Finalizes Investment in Nscale and Joint Venture in Narvik</title>
  1995. <link>https://thenewsthisweek.co.uk/aker-finalizes-investment-in-nscale-and-joint-venture-in-narvik-27212/</link>
  1997. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
  1998. <pubDate>Mon, 13 Oct 2025 17:01:00 +0000</pubDate>
  1999. <category><![CDATA[Brand Post]]></category>
  2000. <guid isPermaLink="false">https://thenewsthisweek.co.uk/aker-finalizes-investment-in-nscale-and-joint-venture-in-narvik-27212/</guid>
  2001.  
  2002. <description><![CDATA[Aker ASA (&#8220;Aker&#8221;) has finalized subscription to shares in the previously announced Series B financing round in Nscale Global Holdings Ltd. (&#8220;Nscale&#8221;). In parallel, Aker and Nscale have completed the closing of the 50/50% joint venture in Narvik, Northern Norway. The new company, &#8220; Aker Nscale &#8220;, will deliver secure, scalable, and energy-efficient infrastructure tailored [&#8230;]]]></description>
  2003. <content:encoded><![CDATA[<p>
  2004.                  <b>Aker ASA (&#8220;Aker&#8221;) has finalized subscription to shares in the previously announced Series B financing round in Nscale Global Holdings Ltd. (&#8220;Nscale&#8221;). In parallel, Aker and Nscale have completed the closing of the 50/50% joint venture in Narvik, Northern Norway. The new company, &#8220;</b><br />
  2005.                  <i><br />
  2006.                    <b>Aker Nscale</b><br />
  2007.                  </i><br />
  2008.                  <b>&#8220;, will deliver secure, scalable, and energy-efficient infrastructure tailored for sovereign AI workloads across Europe.</b>
  2009.                </p>
  2010. <p>
  2011.                  <span class="legendSpanClass">OSLO, Norway</span>, <span class="legendSpanClass">Oct. 13, 2025</span> /PRNewswire/ &#8212; The joint venture has already gained strong commercial traction, anchored by the previously announced five-year, multi-billion dollar off-take agreement with Microsoft, alongside the Stargate Norway project with OpenAI. These partnerships affirm the scale and strategic importance of the business, highlighting the accelerating demand for clean, sovereign AI compute capacity.</p>
  2012. <p>The closing of Aker Nscale follows the fulfilment of all necessary conditions, and the completion of Nscale&#8217;s Series B financing round, in which Aker became a 9.3% owner on a fully diluted basis. Aker&#8217;s 50% stake in Aker Nscale is convertible into additional Nscale shares at a future IPO, positioning Aker to benefit from long-term value creation and public market upside.</p>
  2013. <p>Øyvind Eriksen, President and CEO at Aker ASA, commented:</p>
  2014. <p>&#8220;This reflects the full scope of Aker&#8217;s strategic commitment – through our direct ownership in Nscale and our partnership in Narvik. Together, it gives us a strong position in a fast-moving market, with a structure designed to capture long-term upside. But this is also something bigger: we are finally realizing Narvik&#8217;s potential, placing Norway at the heart of a new industrial era, and doing it in partnership with the most capable technology companies in the world.&#8221;</p>
  2015. <p>Aker Nscale will be headquartered at Fornebu, Norway, with operational teams in Narvik. Kristian Røkke has been appointed Chief Executive Officer of the new company. He commented:</p>
  2016. <p>&#8220;I want to thank the people of Narvik and Northern Norway for their unwavering support and collaboration. Their commitment has been instrumental in turning a bold vision into a real, operational foundation for sovereign AI infrastructure. I&#8217;ve had the opportunity to work closely with local partners and municipalities, and to witness first-hand the capabilities and dedication that define this region. Aker Nscale is built on a clear and growing need: scalable, secure, and energy-efficient compute capacity for European AI. I&#8217;m proud to lead this effort and work alongside our teams, customers, and partners to realize its full potential.&#8221;</p>
  2017. <p>Media contact:<br /></br>Atle Kigen, Head of Media Relations and Public Affairs<br /></br>+47 90 78 48 78<br /></br><a href="mailto:atle.kigen@akerasa.com" target="_blank" rel="nofollow">atle.kigen@akerasa.com</a></p>
  2018. <p>Investor contact:<br /></br>Fredrik Berge, Head of Investor Relations<br /></br>+47 45 03 20 90<br /></br><a href="mailto:fredrik.berge@akerasa.com" target="_blank" rel="nofollow">fredrik.berge@akerasa.com</a></p>
  2019. <p>For more information about the companies, visit <u><a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531434-1&amp;h=2442963931&amp;u=https%3A%2F%2Fwww.akerasa.com&amp;a=www.akerasa.com" target="_blank" rel="nofollow">www.akerasa.com</a></u> and <u><a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531434-1&amp;h=1645224756&amp;u=https%3A%2F%2Fwww.nscale.com&amp;a=www.nscale.com" target="_blank" rel="nofollow">www.nscale.com</a></u></p>
  2020. <p>This information was brought to you by Cision <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531434-1&amp;h=1359838291&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com" target="_blank" rel="nofollow">http://news.cision.com</a></p>
  2021. <p>
  2022.                  <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4531434-1&amp;h=232049687&amp;u=https%3A%2F%2Fnews.cision.com%2Faker-asa%2Fr%2Faker-finalizes-investment-in-nscale-and-joint-venture-in-narvik%2Cc4246455&amp;a=https%3A%2F%2Fnews.cision.com%2Faker-asa%2Fr%2Faker-finalizes-investment-in-nscale-and-joint-venture-in-narvik%2Cc4246455" target="_blank" rel="nofollow">https://news.cision.com/aker-asa/r/aker-finalizes-investment-in-nscale-and-joint-venture-in-narvik,c4246455</a>
  2023.                </p>
  2024. <p id="PURL">
  2025.                  <img loading="lazy" decoding="async" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=EN96500&amp;sd=2025-10-13"></img> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.co.uk/news-releases/aker-finalizes-investment-in-nscale-and-joint-venture-in-narvik-302582292.html" target="_blank">https://www.prnewswire.co.uk/news-releases/aker-finalizes-investment-in-nscale-and-joint-venture-in-narvik-302582292.html</a></p>
  2026. <p>              <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN96500&amp;Transmission_Id=202510131301PR_NEWS_EURO_ND__EN96500&amp;DateId=20251013" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>
  2027. ]]></content:encoded>
  2031. </item>
  2032. </channel>
  2033. </rss>
  2034.  

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

  1. Download the "valid RSS" banner.

  2. Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)

  3. Add this HTML to your page (change the image src attribute if necessary):

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=https%3A//thenewsthisweek.co.uk/feed/

Home · About · News · Docs · Terms

 
Copyright © 2002-9 Sam Ruby, Mark Pilgrim, Joseph Walton, and Phil Ringnalda